

**ANNUAL REPORT : 2019 - 2020**



**DINESH REMEDIES LIMITED**

(CIN: U24230GJ2005PLC045447)

**Regd. Office: Shri Dinesh Mills premises, Akota Road, Vadodara - 390 020**

**Factory: Village Mahuvad, Haranmal Road, Padra-Jambusar Highway,  
Taluka Padra District Vadodara - 391 440**

**DINESH REMEDIES LIMITED**

(CIN – U24230GJ2005PLC045447)

Regd. Office : Shri Dinesh Mills premises, Akota Road, Baroda – 390 020

Phone No. (0265) 2960060 / 61 / 62 / 63 / 64

Email : [cs@dineshremedies.com](mailto:cs@dineshremedies.com) Website: [www.dineshremedies.com](http://www.dineshremedies.com)

=====

**NOTICE**

**NOTICE** is hereby given that, Fifteenth Annual General Meeting of the Members of Dinesh Remedies Ltd. will be held at the Registered Office of the Company at Shri Dinesh Mills Premises, Akota Road, Vadodara on Wednesday, 5<sup>th</sup> August, 2020 at 5.00 p.m. to transact the following business.

**ORDINARY BUSINESS:**

1. To consider and adopt the Audited Financial Statement of the Company for the financial year ended 31<sup>st</sup> March, 2020, the Boards' Report and Auditors' Report thereon.
2. To appoint a Director in place of Shri Dixit Patel (DIN: 01169162), who retires by rotation and being eligible, offers himself for re-appointment.

**Regd. Office:**

Shri Dinesh Mills Premises  
Akota Road,  
Vadodara – 390 020  
Date: 25<sup>th</sup> June, 2020

By Order of the Board,  
**For DINESH REMEDIES LIMITED,**

Sd/-  
**S. K. SHUKLA**  
**COMPANY SECRETARY**

**NOTE:**

1. A MEMBER ENTITLED TO ATTEND AND VOTE AT THE MEETING IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE INSTEAD OF HIMSELF AND A PROXY NEED NOT BE A MEMBER OF THE COMPANY.
2. THE BRIEF DETAILS OF SHRI DIXIT PATEL IS ATTACHED AS ANNEXURE TO THE NOTICE

**ANNEXURE TO THE NOTICE**

**ANNEXURE: A**

Name	<b>Shri DIXIT RASHMIKANT PATEL</b>		
Age	43 years		
Qualification	S. Y. B.Com.		
Expertise	Overall Business Management		
Tenure	Director of the Company since 07-09-2018		
Shareholding in the Company	3139715 (13.31%) Equity share of Rs. 10/- each jointly with Shri Rashmikant Chhaganbhai Patel and Mrs. Chandrikaben R Patel		
Other Directorship etc.:			
<b>Sr. No.</b>	<b>Name of the Company / LLP</b>	<b>Position held</b>	<b>Member/Chairman of the Committee of the Company</b>
1	URVAKUNJ NICOTIN LLP	Designated Partner	Not Applicable

Inter Relationship: He is not related to any Director of the Company.

**Regd. Office:**

Shri Dinesh Mills Premises  
Akota Road,  
Vadodara – 390 020  
Date: 25<sup>th</sup> June, 2020

By Order of the Board,  
**For DINESH REMEDIES LIMITED,**

Sd/-  
**S. K. SHUKLA**  
**COMPANY SECRETARY**

## BOARDS' REPORT

To,  
The Members,  
Dinesh Remedies Limited

Your Directors have pleasure in presenting their Report for the year ended 31<sup>st</sup> March, 2020:

### 1. PERFORMANCE OF THE COMPANY

(Rs. In Lakhs)		
Particulars	2019 – 2020	2018 – 2019
<b>Sales Turnover (Net)</b>	<b>1934.69</b>	<b>2065.70</b>
<b>Gross Profit</b>	<b>78.82</b>	<b>110.17</b>
Less: (A) Depreciation	<b>161.65</b>	<b>155.84</b>
(B) Provision for taxation:		
(i) Current Tax	<b>NIL</b>	<b>NIL</b>
(ii) Deferred Tax	<b>NIL</b>	<b>NIL</b>
<b>Net Profit</b>	<b>(82.83)</b>	<b>(45.67)</b>
<b>Profit available for Appropriation</b>	<b>NIL</b>	<b>NIL</b>
<b>Amount Transferred to Reserves</b>	<b>NIL</b>	<b>NIL</b>

### 2. DIVIDEND

During the year under review, the Company has incurred loss of Rs. 82.83 Lakhs and there is also a carry forward losses and therefore, the Board of Directors do not recommend dividend on equity shares of the Company.

### 3. TRANSFER OF UNCLAIMED DIVIDEND TO INVESTOR EDUCATION AND PROTECTION FUND (IEPF)

As the Company has not declared / paid any dividend since incorporation of the Company and therefore, the provisions relating to transfer of unclaimed dividend to IEPF does not apply to the Company.

### 4. THE STATE OF AFFAIRS OF THE COMPANY

**(A) REVIEW OF OPERATIONS:** During the year under review, Net Sales Turnover has been reduced from Rs.2065.70 Lakhs to 1934.69 Lakhs and losses has also increased from Rs. 45.67 Lakhs to 82.83 Lakhs as compared to the corresponding period of previous year especially due to cut throat competition, liquidity issues, increase in Gelatin price and COVID-19 pandemic despite controlling costs. The liquidity in the market and the price realization is still not showing much improvement in the domestic and International markets mainly due to COVID-19 pandemic.

#### **(B) FINANCIAL HIGHLIGHTS:**

(Rs. in Lakhs)		
Particulars	2019 – 2020	2018 – 2019
<b>Sales Turnover (Net)</b>	<b>1934.69</b>	<b>2065.70</b>
Operating profit (PBDIT)	<b>139.80</b>	<b>169.23</b>
Depreciation	<b>161.65</b>	<b>155.84</b>
Interest	<b>60.98</b>	<b>59.06</b>
Profit before Tax	<b>(82.83)</b>	<b>(45.67)</b>
Tax	<b>NIL</b>	<b>NIL</b>
Net Profit	<b>(82.83)</b>	<b>(45.67)</b>

**(C) OVERALL OUTLOOK:** Despite COVID-19 pandemic adverse impact in the Domestic and International markets, the Company has been taking appropriate steps to increase the sales turnover but the profitability would be under pressure during the current financial year. This forward looking statement would be subject to containment of the Coronavirus and its impact in the domestic & international markets.

**(D)** There is no change in the nature of the business of the Company.

## **5. MATERIAL CHANGES AND COMMITMENT, IF ANY**

There are no material changes and commitments affecting the financial position of the Company occurred from 1<sup>st</sup> April, 2020 to the date of this Report except partial adverse impact due to COVID-19 pandemic lockdown.

## **6. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO**

The information pertaining to conservation of energy, technology absorption, Foreign Exchange Earnings and outgo as required under Section 134 (3)(m) of the Companies Act, 2013 read with Rule 8(3) of the Companies (Accounts) Rules, 2014 is furnished in **Annexure – “A”** attached to this Report.

## **7. RISK MANAGEMENT**

The Company has been taking appropriate actions from time to time to mitigate adverse impact of various Risks viz. Interest rate, gelatin price, foreign exchange, business operations, COVID-19 pandemic and changes in the Regulatory requirements etc. which may adversely affect the performance of the Company. The provisions relating to Risk Management Committee is not applicable to the Company.

## **8. THE CORPORATE SOCIAL RESPONSIBILITY**

As the provisions relating to the Corporate Social Responsibility (CSR) as prescribed u/s. 135 of the Companies Act, 2013 along with Rules made thereunder are not applicable to our Company and therefore, neither the CSR Committee nor the CSR Policy are required to be framed by the Company.

## **9. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS**

During the year under review, the Company has not given any loans, guarantees or made investments pursuant to Section 186 of the Companies Act, 2013

## **10. CONTRACTS / ARRANGEMENTS WITH THE RELATED PARTIES**

During the year under review, no contracts / arrangements are entered with the Related Parties pursuant to Section 188 of the Companies Act, 2013.

## **11. COMPLIANCE OF SECRETARIAL STANDARDS**

The Company has complied with the Secretarial Standard 1 (SS-1) relating to the meetings of the Board of Directors and Secretarial Standard 2 (SS-2) relating to the General meetings issued by the Institute of Company Secretarial of India and approved by the Central Government which are effective from 1<sup>st</sup> October, 2017.

## **12. AUDITORS REPORTS**

The Auditors' Report issued by M/s. Dhirubhai Shah & Co. LLP on the Accounts is self-explanatory and therefore, does not call for any explanation. There were no qualifications, reservations or adverse remarks made by the above referred Statutory Auditors.

The Secretarial Audit issued by the Secretarial Auditor, M/s. Nilesh Savaliya & Associates, Practicing Company Secretary is self-explanatory and therefore, does not call for any explanation. There were no qualifications, reservations or adverse remarks made by the above referred Secretarial Auditor. The copy of the Secretarial Audit Report is attached as **Annexure – "B"**.

## **13. COMPANY'S POLICY RELATING TO DIRECTORS APPOINTMENT, PAYMENT OF REMUNERATION AND DISCHARGE OF THEIR DUTIES**

The Company has the Remuneration Policy as recommended by the Nomination & Remuneration Committee of Directors of the Company relating to appointment of Directors, Key Managerial Personnel and payment of Managerial remuneration, Directors' qualifications, positive attributes, independence of Directors and other related matters pursuant to Section 178(3) of the Companies Act, 2013.

## **14. ANNUAL RETURN**

The extracts of Annual Return pursuant to the provisions of Section 92 read with Rule 12 of the Companies (Management and Administration) Rules, 2014 is attached as **Annexure – "C"** to this Report which can also be viewed on the website of the Company.

## **15. THE MEETINGS OF THE BOARD OF DIRECTORS**

During the year under review, four meetings of Board of Directors of the Company were held on 10/05/2019, 31/07/2019, 05/11/2019 and 03/02/2020.

## **16. KEY MANAGERIAL PERSONNEL (KMP)**

Shri Nimish Patel, Chairman & Managing Director, Shri S K Shukla, Company Secretary and Shri Bindesh Patel, Chief Financial Officer are the KMP of the Company pursuant to Section 203 of the Companies Act, 2013 and the Rules made thereunder.

## **17. SUBSIDIARIES, JOINT VENTURES AND ASSOCIATE COMPANIES**

The Company does not have any Subsidiary, Joint venture or Associate Company.

## **18. DEPOSITS**

The Company has neither accepted nor renewed any Deposits since its incorporation.

## 19. DIRECTORS

Pursuant to Section 149 and 152 of the Companies Act, 2013 read with the Companies (Appointment and Qualification of Directors) Rules, 2014, Independent Directors are not liable to retire by rotation whereas other Directors are liable to retire by rotation and accordingly, Shri Dixit Patel, Director of the Company would retire by rotation and being eligible, offer himself for re-appointment. The particulars of the Director retiring by rotation and seeking re-appointment have been given in the Notice of the ensuing 15<sup>th</sup> Annual General Meeting of the members of the Company.

During the year under review, Shri Manishbhai Patel has resigned as Director of the Company with effect from 18<sup>th</sup> March, 2020.

## 20. DECLARATION OF INDEPENDENT DIRECTORS

The Independent Directors have given the declaration that, they meet the criteria of independence as provided in Section 149(6) of the Companies Act, 2013 read with Rules made thereunder.

## 21. PERFORMANCE EVALUATION OF DIRECTORS

The performance evaluation of all the Directors including Independent Directors and the Board as a whole which includes the Committees thereof was done on 3<sup>rd</sup> February, 2020 as per the Performance Evaluation Policy of the Company. As per provisions of the Companies Act, 2013 read with Rules made thereunder, a separate meeting of the Independent Directors was held on 3<sup>rd</sup> February, 2020 to consider the following agenda:

- a) Review the performance of Non-Independent directors and the Board as a whole including committees thereof.
- b) Review the performance of the Chairperson of the Company.
- c) Asses the efficacy and adequacy of flow of information.

All the Independent Directors were present in the meeting held on 3<sup>rd</sup> February, 2020 and considered the above referred agenda.

## 22. COMPOSITION OF AUDIT COMMITTEE AND VIGIL MECHANISM

The Audit Committee consists of three Independent Directors viz. Shri Paresh Saraiya, Chairman of the Audit Committee, Shri Sanjiv Shah and Shri Sujit Bhayani are the members of the Audit Committee

The provisions relating to vigil mechanism are not applicable to the Company.

## 23. SHARES

- (a) **BUY BACK OF SECURITIES:** The Company has not bought back any of its securities during the year under review.
- (b) **SWEAT EQUITY:** The Company has not issued any Sweat Equity Shares during the year under review.
- (c) **BONUS SHARES:** No Bonus Shares were issued during the year under review.
- (d) **EMPLOYEES STOCK OPTION PLAN:** The Company has not provided any Stock Option Scheme to the employees.

## **24. INTERNAL CONTROL SYSTEMS AND THEIR ADEQUACY**

The Internal Audit department conducts audit of all departments of the Company and places Audit reports/plans before the Audit Committee which reviews adequacy of internal audit functions, audit procedures and its coverage periodically. The minutes of the Audit Committee meetings are placed at the meetings of the Board of Directors from time to time. The Company has adopted the concept of pre-audit and therefore, the mistakes, if any are rectified before the transactions are finally booked in the Accounts of the Company. The provisions relating to appointment of Internal Auditor pursuant to Section 138 of the Companies Act, 2013 & Rules made thereunder are not applicable to the Company.

## **25. INDUSTRIAL RELATIONS**

During the year under review, industrial relations have remained cordial. As on 31<sup>st</sup> March, 2020, there were 88 employees in the Company.

There is no employee drawing the remuneration exceeding the limits prescribed under Rule 5(2) of the Companies (Appointment & Remuneration of Managerial Personnel) Rules, 2014.

## **26 SEXUAL HARRASSMENT OF WOMAN EMPLOYEES**

The Company had formed the Committee to deal with the complaints, if any regarding sexual harassment of woman employees and no complaint was received by the Committee during the financial year 2019–2020.

## **27. INSURANCE:**

All the properties of the Company including buildings, plant & machinery and stocks have been insured

## **28. DIRECTORS RESPONSIBILITY STATEMENT**

Your Directors confirm that:

- (a) in the preparation of the Annual Accounts for the financial year 2019–2020, the applicable Accounting Standards had been followed along with proper explanation relating to material departures;
- (b) the Directors had selected such Accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit and loss of the Company for that period;
- (c) the Directors had taken proper and sufficient care for the maintenance of adequate Accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- (d) the Directors had prepared the Annual Accounts on a going concern basis;  
and



- (e) the Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

## **29. ACKNOWLEDGEMENTS**

Your Board of Directors thanks all the stakeholders viz. shareholders, customers, suppliers, bankers, employees for their support during the period under review.

**FOR AND ON BEHALF OF THE BOARD,**

Place: Vadodara  
Date: 25<sup>th</sup> June, 2020

Sd/-  
**NIMISH PATEL**  
**CHAIRMAN**

## **ANNEXURE – “A”**

### **A. CONSERVATION OF ENERGY:**

1. The steps taken or impact on Conservation of Energy: **None**
2. The steps taken by the Company for utilizing alternate sources of Energy: **None.**
3. The Capital Investments on Energy Conservation Equipments: **NIL**

### **B. TECHNOLOGY ABSORPTION :**

As no foreign technology is imported, the question of its absorption does not arise.

### **C. FOREIGN EXCHANGE EARNINGS AND OUTGO:**

Total foreign exchange used and earned: **Rs. 43.68** Lakhs and **Rs. 81.41** Lakhs respectively.

## **FORM: A**

### **RESEARCH & DEVELOPMENT:**

The R & D department of the Company is making every effort to improve the quality and has been active in developing the different mixtures of colors being used in manufacturing of the capsules.

**Expenditure on R & D:** Rs.3.24 Lakhs

**FOR AND ON BEHALF OF THE BOARD,**

Place: Vadodara  
Date: 25<sup>th</sup> June, 2020

Sd/-  
**NIMISH PATEL**  
**CHAIRMAN**

**ANNEXURE – “B”**

**FORM NO. MR-3  
SECRETARIAL AUDIT REPORT  
FOR THE FINANCIAL YEAR ENDED ON 31<sup>ST</sup> MARCH, 2020**

[Pursuant to Section 204(1) of the Companies Act, 2013 and Rule 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 and Regulation 24A of the SEBI (Listing Obligation and Disclosure) Regulations, 2015]

**To,  
The Members,  
Dinesh Remedies Limited  
Shri Dinesh Mills Premises, Padra Road, Vadodara – 390 005**

We have conducted the Secretarial Audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **Dinesh Remedies Limited** which is a Material Subsidiary Company of Shri Dinesh Mills Limited (hereinafter called the company), Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/ statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's books, papers, Minutes books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers and authorized representatives during the conduct of secretarial audit, we hereby report that, in our opinion, the Company has, during the audit period covering financial year ended on 31<sup>st</sup> March, 2020, complied with the statutory provisions listed hereunder and also that, the Company has proper board process and compliance mechanism in place to extent in manner and subject to the reporting made here under:

We have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on 31<sup>st</sup> March, 2020 according to the provisions of:

1. The Companies Act, 2013 and the rules made there under
2. The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the Rules made there under
3. Foreign Exchange Management Act, 1999 and the rules and regulations made there under to extent of Foreign Direct Investment and Overseas Direct Investment and External Commercial Borrowings.

We have also examined compliance with the applicable clauses of the following:

(i) Secretarial Standards issued by The Institute of Company Secretaries of India.

During the period under review, the Company has complied with the provisions of the Acts, Rules Regulations, guidelines and standards etc. mentioned above.

Further, as per representation of management letter, considering its nature of business, process and location, the following acts are specifically applicable to the Company. There are adequate system and process in the Company to monitor and ensure compliance:

1. The Water (Prevention and Control of Pollution) Act, 1974 and Rules
2. The Air (Prevention and Control of Pollution) Act, 1981 and Rules
3. Environment Protection Act, 1986 and Rules
4. Water Cess Act, 1977 and Rules

**We further report that;**

The Board of Directors of the Company is duly constituted with the proper balance of executive directors, non-executive directors and independent directors. Shri Manishbhai Ishwarbhai Patel (DIN: 01120586) resigned as Director of the Company with effect from 18/03/2020. The change in the composition of the Board of Directors that took place during the period under review was carried out in compliance with the provisions of the Act.

Adequate notice is given to all directors to schedule the Board Meetings including Committees thereof, Agenda and detailed notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

All the decision is carried by majority and there were no dissent given by any members of the Board including committees thereof.

We further report that, there are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

We further report that, during the period under review, Annual General Meeting was held on 31/07/2019 and following Special Resolutions were passed:

- (a) Shri Pareshbhai Saraiya (DIN: 00063971) was re-appointed as Independent director of the Company for a further period of five years from 01/04/2019 to 31/03/2024.
- (b) Shri Sanjivbhai Shah (DIN: 00065796) was re-appointed as Independent director of the Company for a further period of five years from 01/04/2019 to 31/03/2024.
- (c) Shri Sujitbhai Bhayani (DIN: 01767427) was re-appointed as Independent director of the Company for a further period of five years from 01/04/2019 to 31/03/2024.

**For Nilesh Savaliya & Associates**

Place: Surat  
Date : 17/06/2020  
UDIN: A051007B000350691

Sd/-

---

**Nileshkumar Shantibhai Savaliya**  
Membership No.: 51007  
CP No.: 18632

**ANNEXURE – “C”  
FORM No. MGT-9**

**EXTRACT OF ANNUAL RETURN**

**as at the Financial Year ended on 31<sup>st</sup> March, 2020**

[Pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014]

**I. REGISTRATION AND OTHER DETAILS:**

(i)	Corporate Identification Number (CIN)	<b>U24230GJ2005PLC045447</b>
(ii)	Registration Date	<b>09/02/2005</b>
(iii)	Name of the Company	<b>DINESH REMEDIES LIMITED</b>
(iv)	Category / Sub-Category of the Company	<b>Indian Non-Govt. Company</b>
(v)	Address of the Registered office and contact details	<b>Shri Dinesh Mills premises, Akota Road, Vadodara – 390020</b>
(vi)	Whether Listed company	<b>NO – Unlisted Public Company</b>
(vii)	Name, Address and Contact details of Registrar and Transfer Agent, if any	<b>None – Not Applicable</b>

**II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY :**

All the business activities contributing 10 % or more of the total turnover of the company shall be stated:-

Sr. No.	Name and Description of main products / services	NIC Code of the Product/service	% to total turnover of the Company
1.	Empty Hard Gelatin Capsules Shells	21009	100%

**III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES:**

Sr. No.	Name and Address of the Company	CIN/GLN	Holding / Subsidiary / Associate	% of shares held	Applicable Section
1	Shri Dinesh Mills Limited	L17110GJ1935PLC000494	HOLDING	55.52%	Section 2(46)

**IV. SHARE HOLDING PATTERN: (Equity Share Capital Breakup as percentage of Total Equity)**

**(i) Category-wise shareholding**

Category of Shareholders	No. of Shares held at the beginning of the year (1 <sup>st</sup> April, 2019)				No. of Shares held at the end of the year (31 <sup>st</sup> March, 2020)				% Change during the year
	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	
<b>A.Promoters</b>									
<b>(1) Indian</b>									
a) Individual/HUF	0	3139720	3139720	13.31%	0	3139720	3139720	13.31%	NIL
b) Central Govt.	0	0	0	0	0	0	0	0	NIL
c) State Govt.(s)	0	0	0	0	0	0	0	0	NIL
d) Bodies Corporate	0	13098095	13098095	55.52%	0	13098095	13098095	55.52%	NIL
e) Banks / FI	0	0	0	0	0	0	0	0	NIL
f) Any other	0	0	0	0	0	0	0	0	NIL
<b>Sub Total (A) (1):-</b>	<b>0</b>	<b>16237795</b>	<b>16237795</b>	<b>68.83%</b>	<b>0</b>	<b>16237795</b>	<b>16237795</b>	<b>68.83%</b>	<b>NIL</b>



<b>b) Individuals</b>									
i) Individual shareholders holding nominal share capital upto Rs. 1/- lakh.	0	0	0	0	0	0	0	0	0
ii) Individual shareholders holding nominal share capital in excess of Rs. 1/- Lakh	0	0	0	0	0	0	0	0	0
<b>c)Others, (specify)</b>									
Non Resident Indians	0	0	0	0	0	0	0	0	0
Overseas Corporate Bodies	0	0	0	0	0	0	0	0	0
Foreign Nationals	0	0	0	0	0	0	0	0	0
Clearing Members	0	0	0	0	0	0	0	0	0
Trusts	0	0	0	0	0	0	0	0	0
Foreign Bodies - D R	0	0	0	0	0	0	0	0	0
<b>Sub-total (B)(2):-</b>	0	0	0	0	0	0	0	0	0
<b>Total Public Shareholding (B)= (B)(1)+ (B)(2)</b>	0	0	0	0	0	0	0	0	0
<b>C.Shares held by Custodian for GDRs &amp; ADRs</b>	0	0	0	0	0	0	0	0	0
<b>Grand Total (A+B+C)</b>	0	23591580	23591580	100%	0	23591580	23591580	100%	NIL



**(ii) Shareholding of Promoters:**

Sr. No.	Shareholder's Name	Shareholding at the beginning of the year (i.e. 1 <sup>st</sup> April, 2019)			Shareholding at the end of the year (i.e. 31 <sup>st</sup> March, 2020)			% change in share holding during the year
		No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	
1	Shri Dinesh Mills Limited	13098095	55.52%	0	13098095	55.52%	0	0
2	Star Capsules LLC, USA	7375765	31.17%	0	7375765	31.17%	0	0
3	Shri Rashmikanbhai C. Patel Joint with Mrs. Chandrikaben Patel and Shri Dixit R Patel	3139715	13.31%	0	3139715	13.31%	0	0
4	Shri Bharatbhai U. Patel Jointly With Shri Nimishbhai U. Patel	1	0	0	1	0	0	0
5	Shri Bharatbhai U. Patel	1	0	0	1	0	0	0
6	Shri Nimishbhai U. Patel	1	0	0	1	0	0	0
7	Mrs. Roopaben B. Patel	1	0	0	1	0	0	0
8	Mrs. Arushaben N. Patel	1	0	0	1	0	0	0

**(iii) Change in Promoters' Shareholding (please specify, if there is no change)**

Sr. No.		Shareholding at the beginning of the year (1 <sup>st</sup> April, 2019)		Cumulative Shareholding during the Year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
1	At the beginning of the year (1 <sup>st</sup> April, 2019)	23591580	100%	0	0
2	Date wise Increase / Decrease in Promoters Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc.)	0	0	0	0
3	At the end of the year (31 <sup>st</sup> March, 2020)	23591580	100%	0	0

**(iv) Shareholding Pattern of top 10 shareholders (other than Directors, Promoters and Holders of GDRs and ADRs)**

Sr. No.		Shareholding at the beginning of the year		Cumulative Shareholding during the Year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
	<b>For each of the top 10 shareholders</b>				
	At the beginning of the year	0	0	0	0
	Date wise Increase/Decrease in Shareholding during the year specifying the reasons for increase/decrease (e.g. allotment/transfer/bonus/sweat equity etc):	0	0	0	0
	At the end of the year (or on the date of separation, if separated during the year)	0	0	0	0

**(v) Shareholding of Directors and Key Managerial Personnel:**

Sr. No.	<b>Shareholding of each Directors and each Key Managerial Personnel</b>	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	% of total shares of the Company	No. of shares	% of total shares of the Company
	At the beginning of the year (01/04/2019) (1) Shri B U Patel = 02 shares (2) Shri N U Patel = 01 share (CMD-KMP) (3) Shri R C Patel = 31,39,715 shares (4) Shri Manish Patel = Nil (Upto: 18/03/2020) (5) Shri Paresh Saraiya = NIL (6) Shri Sanjiv Shah = NIL (7) Shri Sujit Bhayani = NIL (8) Shri S K Shukla = NIL (CS-KMP) (9) Shri Bindesh Patel = NIL (CFO-KMP)	31,39,718	13.31	0	0
	Date wise Increase / Decrease in Shareholding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc.)	0	0	0	0
	At the end of the year (31/03/2020) (1) Shri B U Patel = 02 shares (2) Shri N U Patel=01 share (CMD-KMP) (3) Shri R C Patel = 31,39,715 shares (4) Shri Paresh Saraiya = NIL (5) Shri Sanjiv Shah = NIL (6) Shri Sujit Bhayani = NIL (7) Shri S K Shukla = NIL (CS-KMP) (8) Shri Bindesh Patel=NIL (CFO-KMP)	31,39,718	13.31	0	0

**V. INDEBTEDNESS:** Indebtedness of the Company including interest outstanding/accrued but not due for payment

(Rs. In Lakhs)

	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
<b>Indebtedness at the beginning of the financial year (i.e. 01/04/2019)</b>				
i) Principal Amount	208.70	0	0	208.70
ii) Interest due but not paid	0.00	0	0	0.00
iii) Interest accrued but not due	0.00	0	0	0.00
<b>Total (i + ii + iii)</b>	208.70	0	0	208.70
<b>Change in Indebtedness during the financial year (2019 – 2020)</b>				
* Addition	101.58	0	0	101.58
* Reduction	179.81	0	0	179.81
<b>Net Change</b>	78.23	0	0	78.23
<b>Indebtedness at the end of the financial year (i.e. 31/03/2020)</b>				
i) Principal Amount	130.47	0	0	130.47
ii) Interest due but not paid	0.00	0	0	0.00
iii) Interest accrued but not due	0.00	0	0	0.00
<b>Total ( i + ii + iii )</b>	130.47	0	0	130.47

**VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL:**

*A. Remuneration to Managing Director, Whole-time Directors and/or Manager:*

Sr. No.	Particulars of Remuneration	Name of MD/WTD/ Manager	Total Amount
		Shri N. U. Patel (C.M.D.)	
1	Gross salary	Nil	Nil
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	Nil	Nil
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961	Nil	Nil
	(c) Profits in lieu of salary under section 17(3) Income- tax Act, 1961	Nil	Nil
2	Stock Option	Nil	Nil
3	Sweat Equity	Nil	Nil
4	Commission - as % of profit - others, specify	Nil	Nil
5	Others, please specify	Nil	Nil
	Total (A)	Nil	Nil
	Ceiling as per the Act	Nil	Nil

**B. Remuneration to other Directors**

Sr. No.	Particulars of Remuneration	Name of Directors						Total Amount (Rs.)
		PMS	SMS	SJB	DRP	MIP	BUP	
1	Independent Directors	19000	15000	11000	0	0	0	45000
	Fee for attending board / committee meetings							
	Commission	0	0	0	0	0	0	0
	Others, please specify	0	0	0	0	0	0	0
	Total (1)	19000	15000	11000	0	0	0	45000
2	Other Non-Executive Directors							
	Fee for attending board committee meetings	0	0	0	10000	0	0	10000
	Commission	0	0	0	0	0	0	0
	Others, please specify	0	0	0	0	0	0	0
	Total (2)	0	0	0	10000	0	0	10000
	Total (B)=(1+2)	19000	15000	11000	10000	0	0	55000
	Total Managerial Remuneration							
	Overall Ceiling as per the Act	-	-	-	-	-		-

PMS: Shri Paresh M. Saraiya, SMS: Shri Sanjiv M. Shah, SJB: Shri Sujit J. Bhayani, DRP: Shri Dixit R. Patel, MIP: Shri Manish I. Patel and BUP: Shri Bharat U. Patel

**C. Remuneration to Key Managerial Personnel other than MD /Manager / WTD during the financial year 2019 – 2020**

Sr. No.	Particulars of Remuneration	Key Managerial Personnel			
		CEO	CS	CFO	Total
1	Gross salary	Nil	1.02 Lacs	6.35 Lacs	7.37 Lacs
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	Nil			
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961	Nil	Nil	Nil	Nil
	(c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961	Nil	Nil	Nil	Nil
2	Stock Option	Nil	Nil	Nil	Nil
3	Sweat Equity	Nil	Nil	Nil	Nil
4	Commission	Nil	Nil	Nil	Nil
	- as % of profit	Nil	Nil	Nil	Nil
	others, specify	Nil	Nil	Nil	Nil
5	Others, please specify	Nil	Nil	Nil	Nil
	Total	Nil	1.02 Lacs	6.35 Lacs	7.37 Lacs

CEO: Chief Executive Officer,

CS: Company Secretary,

CFO: Chief Financial Officer

**VII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:**

Type	Section of the Companies Act	Brief Description	Details of Penalty / Punishment/ Compounding fees imposed	Authority [RD / NCLT/ COURT]	Appeal made, if any (give Details)
<b>A. COMPANY</b>					
Penalty	N.A.	None	None	None	None
Punishment	N.A.	None	None	None	None
Compounding	N.A.	None	None	None	None
<b>B. DIRECTORS</b>					
Penalty	N.A.	None	None	None	None
Punishment	N.A.	None	None	None	None
Compounding	N.A.	None	None	None	None
<b>C. OTHER OFFICERS IN DEFAULT</b>					
Penalty	N.A.	None	None	None	None
Punishment	N.A.	None	None	None	None
Compounding	N.A.	None	None	None	None

**FOR AND ON BEHALF OF THE BOARD,**

Place: Vadodara  
Date: 25<sup>th</sup> June, 2020

Sd/-  
**NIMISH PATEL**  
**CHAIRMAN**

## **Independent Auditor's Report**

### **To the Members of Dinesh Remedies Limited**

#### **Report on the Standalone Financial Statements**

#### **Opinion**

We have audited the standalone financial statements of Dinesh Remedies Limited ("the Company"), which comprises of the balance sheet as at 31st March 2020, and the statement of Profit and Loss (including other comprehensive income), and the Statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2020, and loss, changes in equity, and its cash flows for the year ended on that date.

#### **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### **Key Audit Matters**

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. In our opinion, there are no reportable Key Audit Matters for the standalone financial statements of the Company.

#### **Management's Responsibility for the Standalone Financial Statements**

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under Section 133 of the Act.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate implementation and maintenance of accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

### **Auditor's Responsibilities for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

### **Report on Other Legal and Regulatory Requirements**

1. As required by the Companies (Auditor's Report) Order, 2016 ("the Order") issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the Annexure A, a statement on the matters specified in the paragraph 3 and 4 of the order.

2. As required by Section 143 (3) of the Act, we report that:

- a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
- b. In our opinion proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
- c. The Balance Sheet, the Statement of Profit and Loss and the Cash Flow statement dealt with by this Report are in agreement with the books of account;
- d. In our opinion, the aforesaid standalone financial statements comply with the Indian Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014;
- e. On the basis of the written representations received from the directors as on 31<sup>st</sup> March 2020 taken on record by the Board of Directors, none of the directors is disqualified as on 31<sup>st</sup> March 2020 from being appointed as a director in terms of Section 164 (2) of the Act;
- f. With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate report in "Annexure B"; and

- g. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
- i. the Company has disclosed the impact, wherever necessary, of pending litigations on its financial position in its financial statements;
  - ii. the Company has made provision, as required under the applicable law or Indian Accounting Standards, for material foreseeable losses, if any, on long-term contracts including derivative contracts;
  - iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company.

**For Dhirubhai Shah & Co LLP**

*Chartered Accountants*

Firm's registration number: 102511W/W100298

**Harish B Patel**

*Partner*

Membership number: 014427

Place: Vadodara

Date: 25<sup>th</sup> June, 2020



## **ANNEXURE - A TO INDEPENDENT AUDITOR'S REPORT**

The Annexure referred to in Independent Auditors' Report to the members of the company on the standalone financial statements for the year ended 31 March 2020, we report that:

- (i) (a) The company has maintained proper records showing full particulars including quantitative details and situation of fixed assets.
- (b) As explained to us, the fixed assets have been physically verified by the management at reasonable intervals. In our opinion, the programme of verification is reasonable having regard to the size of the company and the nature of its assets. We have been informed that no material discrepancies were noticed on such verification.
- (c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the title deeds of immovable properties are held in the name of the Company.
- (ii) As explained to us, the inventories have been physically verified during the year by the management. In our opinion, the frequency of verification is reasonable. Discrepancies noticed on physical verification of inventory as compared to book records were not material.
- (iii) The Company has not granted any loans secured or unsecured to companies, firms or other parties covered in the register maintained under section 189 of the Companies Act, and therefore, the provisions of clauses (iii)(a), (iii)(b) & (iii)(c) of the Order are not applicable to the Company.
- (iv) In our opinion and according to the information and explanations given to us, the Company has complied with the provisions of section 185 and 186 of the Act, with respect to the loans and investments made.
- (v) The Company has not accepted any deposits from the public.
- (vi) Company is not required to maintain cost records as per the Companies (Cost Records and Audit) Rules, 2014 prescribed by Central Government under subsection (1) of section 148 of the Companies Act; hence this clause is not applicable to the company.
- (vii) (a) The Company is regular in depositing undisputed statutory dues including provident fund, employees' state insurance, income tax, sales tax, service tax, duty of customs, duty of excise, value added tax, GST, cess and any other statutory dues with the appropriate authorities and does not have any undisputed statutory dues for a period of more than six months from the date they became payable.
- (b) On the basis of our examination of documents and records there are no disputed statutory dues outstanding of income tax, sales tax, service tax, duty of customs, duty of excise, value added tax, GST etc. with the appropriate authorities.
- (viii) In our opinion and according to the information and explanation given to us, the Company has not defaulted in repayment of dues to financial institution, banks, government or debenture holders during the year.

- (ix) In our opinion, and according to the information and explanations given to us, the term loans, if any have been applied for the purposes for which they were obtained.
- (x) According to the information and explanations given to us, no material fraud by the Company or on the Company by its officers or employees has been noticed or reported during the course of our audit.
- (xi) According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not paid/provided for managerial remuneration. Accordingly, paragraph 3(xi) of the order is not applicable.
- (xii) In our opinion and according to the information and explanations given to us, the Company is not a Nidhi company. Accordingly, paragraph 3(xii) of the Order is not applicable.
- (xiii) According to the information and explanations given to us and based on our examination of the records of the Company, transactions with the related parties are in compliance with sections 177 and 188 of the Act where applicable and details of such transactions have been disclosed in the financial statements as required by the applicable accounting standards.
- (xiv) According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year.
- (xv) According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not entered into non-cash transactions with directors or persons connected with him. Accordingly, paragraph 3(xv) of the Order is not applicable
- (xvi) The Company is not required to be registered under section 45-IA of the Reserve Bank of India Act 1934.

**For, Dhirubhai Shah & Co LLP**  
**Chartered Accountants**  
**FRN 102511W/W100298**

**Place: Vadodara**  
**Date: 25<sup>th</sup> June, 2020**

**Harish B Patel**  
**Partner**  
**Membership Number: 014427**

## **Annexure - B to the Auditors' Report**

### **Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")**

We have audited the internal financial controls over financial reporting of Dinesh Remedies Limited ("the Company") as of 31<sup>st</sup> March 2020 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

#### **Management's Responsibility for Internal Financial Controls**

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

#### **Auditors' Responsibility**

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the standalone financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

## **Meaning of Internal Financial Controls over Financial Reporting**

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

## **Inherent Limitations of Internal Financial Controls Over Financial Reporting**

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

## **Opinion**

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31 March 2020, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

**For Dhirubhai Shah & Co LLP**

*Chartered Accountants*

Firm's Registration Number: 102511W/W100298

**Harish B Patel**

*Partner*

Membership Number: 014427

Place: Vadodara

Date: 25<sup>th</sup> June, 2020

**DINESH REMEDIES LIMITED****STATEMENT OF ASSETS AND LIABILITIES AS AT 31st MARCH, 2020**

	Note No.	As at 31-03-2020 Rs. In Lakhs	As at 31-03-2019 Rs. In Lakhs
<b>ASSETS</b>			
<b>NON-CURRENT ASSETS</b>			
(a) Property, Plant and Equipment	4	2,078.05	2,120.26
(b) Capital Work in Progress	4	-	-
(c) Financial Assets			
(ii) Loans	5	28.92	37.56
(d) Other Non Current Assets	6	11.18	14.50
		<u>2118.15</u>	<u>2,172.32</u>
<b>CURRENT ASSETS</b>			
(a) Inventories	7	219.67	284.83
(b) Financial Assets			
(i) Trade Receivables	8	459.30	618.98
(ii) Cash and Cash Equivalents	9	32.78	5.26
(c) Other Current Assets	10	13.27	48.11
		<u>725.02</u>	<u>957.18</u>
<b>TOTAL ASSETS</b>		<u><b>2,843.17</b></u>	<u><b>3,129.50</b></u>
<b>EQUITY AND LIABILITIES</b>			
<b>EQUITY</b>			
(a) Equity Share Capital	11	2,359.16	2,359.16
(b) Other Equity	12	(620.12)	(537.29)
		<u>1,739.04</u>	<u>1,821.87</u>
<b>LIABILITIES</b>			
<b>NON-CURRENT LIABILITIES</b>			
(a) Financial Liabilities			
(i) Borrowings	13	130.83	192.10
(b) Provisions	14	23.54	24.94
		<u>154.37</u>	<u>217.04</u>
<b>CURRENT LIABILITIES</b>			
(a) Financial Liabilities			
(i) Borrowings	15	421.39	244.07
(ii) Trade Payables	16	460.62	621.88
(iii) Other Financial Liabilities	17	50.56	207.65
(b) Other Current Liabilities	18	7.57	14.44
(c) Provisions	19	9.60	2.56
		<u>949.76</u>	<u>1,090.59</u>
<b>TOTAL EQUITY &amp; LIABILITIES</b>		<u><b>2,843.17</b></u>	<u><b>3,129.50</b></u>

Corporate Information, Basis of Preparation & Significant Accounting Policies 1-3

The accompanying notes 1 to 34 are an integral part of the Standalone Financial Statements

"As per our report of even date attached"

ON BEHALF OF THE BOARD OF DIRECTORS

For **DIRUBHAI SHAH & CO LLP**

Chartered Accountants

Firm Registration Number: 102511W/W100298

Chairman & Managing  
Director

Director

**Harish B Patel**

Partner

Membership Number: 014427

Chief Financial Officer

Company Secretary

Place: **Vadodara**

Dated : 25th June, 2020

**DINESH REMEDIES LIMITED****STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31st MARCH, 2020**

	Note No.	2019-20 Rs. In Lakhs	2018-19 Rs. In Lakhs
<b>INCOME</b>			
Revenue from operations	20	1,934.69	2,065.70
Other income	21	17.11	24.49
<b>TOTAL INCOME</b>		<b>1,951.80</b>	<b>2,090.20</b>
<b>EXPENSES</b>			
Cost of Materials Consumed	22	900.67	914.53
Excise Duty			-
Changes in inventories of finished goods, Stock-in-Trade and work-inprogress	23	(41.63)	(8.12)
Employee benefits expense	24	327.86	329.13
Finance Costs	25	60.98	59.06
Depreciation and amortization expenses	4	161.65	155.84
Other expenses	26	622.48	684.83
<b>TOTAL EXPENSES</b>		<b>2,032.01</b>	<b>2,135.27</b>
<b>Profit/(Loss) before exceptional items and tax</b>		<b>(80.21)</b>	<b>(45.07)</b>
Exceptional items (net)		-	-
<b>Profit/(Loss) before tax</b>		<b>(80.21)</b>	<b>(45.07)</b>
Tax items			
Current tax		-	-
Earlier years tax provisions (written back)		-	-
Deferred tax asset / (liability)		-	-
Total tax items		-	-
<b>Profit/(Loss) for the year</b>		<b>(80.21)</b>	<b>(45.07)</b>
<b>Other Comprehensive Income</b>			
Items that will not be re-classified to Profit or Loss			
Re-measurement gains/ (losses) on post employment benefit plans		(2.61)	(0.60)
<b>Other Comprehensive Income/ (Loss) for the year</b>		<b>(2.61)</b>	<b>(0.60)</b>
<b>Total Comprehensive Income/ (Loss) for the year</b>		<b>(82.83)</b>	<b>(45.67)</b>
<b>Earnings Per Equity Share (Basic and Diluted)</b>	27	-	(0.19)
<b>Corporate Information, Basis of Preparation &amp; Significant Accounting Policies</b>	1-3		

The accompanying notes 1 to 34 are an integral part of the Standalone Financial Statements

"As per our report of even date attached"

ON BEHALF OF THE BOARD OF DIRECTORS

For **DHIRUBHAI SHAH & CO LLP**

Chartered Accountants

Firm Registration Number: 102511W/W100298

Chairman & Managing  
Director

Director

**Harish B Patel**

Partner

Membership Number: 014427

Place: Vadodara

Dated : 25th June, 2020

Chief Financial Officer

Company Secretary

**DINESH REMEDIES LIMITED****CASH FLOW STATEMENT FOR THE YEAR ENDED 31st MARCH, 2019**

	2019-20 Rs. In Lakhs	2018-19 Rs. In Lakhs
<b>(A) CASH FLOW FROM OPERATING ACTIVITIES</b>		
<b>Profit/ (loss) Before Tax</b>	<b>(80.21)</b>	(45.07)
Adjustments for:		
Depreciation and amortization	161.65	155.84
Interest and finance charges	60.98	54.76
Interest income	(2.20)	(2.38)
Non-cash adjustment in OCI	(2.61)	(0.60)
Profit on sale of Fix Assets	-	(0.66)
<b>Operating Profit before Working Capital Changes</b>	<b>137.60</b>	161.89
Adjustments for changes in working capital :		
(Increase)/decrease in trade receivables	159.68	42.81
(Increase)/decrease in other assets	46.80	(28.35)
(Increase)/decrease in inventories	65.16	(136.69)
Increase/(decrease) in Trade Payables	(161.25)	206.68
Increase/(decrease) in Other Current Liabilities	(163.95)	(50.54)
Increase/(decrease) in provisions	5.65	4.62
<b>Cash Generated from Operations</b>	<b>89.69</b>	200.41
Income taxes paid	-	-
<b>Net Cashflow from Operating Activities</b>	<b>89.69</b>	<b>200.41</b>
<b>(B) CASH FLOW FROM INVESTING ACTIVITIES</b>		
Purchase of fixed assets	(119.43)	(112.37)
Additions in capital work in progress		(0.58)
Disposal of Fixed Assets		2.02
Transfer of Capital work in progress		-
Purchase of Investments		-
Proceeds from sale of investments		-
Interest received	2.20	2.38
<b>Net Cashflow from Investing Activities</b>	<b>(117.23)</b>	<b>(108.55)</b>
<b>(C) CASH FLOW FROM FINANCING ACTIVITIES</b>		
Long Term Borrowings		
Payments	(61.28)	(160.68)
Short Term Borrowings		
Receipts	177.32	108.64
Payments	-	-
Interest and finance charges	(60.98)	(54.76)
<b>Net Cashflow from Financing Activities</b>	<b>55.07</b>	<b>(106.81)</b>
<b>Net Increase/(Decrease) in Cash and Cash Equivalents</b>	<b>27.53</b>	<b>(14.94)</b>
<b>Cash and bank balances at the beginning of the year</b>	<b>5.26</b>	<b>15.53</b>
<b>Cash and bank balances at the end of the year</b>	<b>32.78</b>	<b>5.26</b>

**NOTES:**

- 1) The above cash flow statement has been prepared as per the "Indirect method" set out in the Indian Accounting Standard (Ind AS) - 7 Statement of Cash Flows
- 2) Figures in bracket indicate cash outflow.
- 3) Previous year figures have been regrouped and recast wherever necessary to confirm to current year's classification.

Cash and cash equivalents at the end of the year consist of cash on hand, cheques, draft on hand and balance with banks as follows:

DETAIL OF CASH AND CASH EQUIVALENTS	As at 31-03-2020 Rs. In Lakhs	As at 31-03-2019 Rs. In Lakhs
Balances with banks		
In current accounts	32.22	4.89
Cash on hand	0.56	0.37
	<b>32.78</b>	<b>5.26</b>

"As per our report of even date attached"

**For DHIRUBHAI SHAH & CO LLP**

Chartered Accountants

Firm Registration Number: 102511W/W100298

**ON BEHALF OF THE BOARD OF DIRECTORS**

Chairman & Managing  
Director

Director

**Harish B Patel**

Partner

Membership Number: 014427

**Place: Vadodara**

**Dated : 25th June, 2020**

Chief Financial Officer

Company Secretary



**DINESH REMEDIES LIMITED**

NOTES ANNEXED TO AND FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31st MARCH, 2020

**4 - PROPERTY, PLANT AND EQUIPMENT****(Rs. In Lakhs)**

	Freehold land	Buildings	Furniture, Fixtures and Furnishing	Plant and Equipments	Electrical Installations	Vehicles	Tubewell and Waterworks	Weighing Scales	Total	Capital Work-In progress
<b>Cost:</b>										
<b>As at 31st March, 2019</b>	59.90	544.15	49.09	2,957.67	92.63	8.63	2.08	0.95	3,715.11	-
Additions	-	0.72	0.53	115.49	2.51	-	-	0.18	119.43	0.00
Disposals / transfers	-	-	-	-	-	-	-	-	-	0.00
<b>As at 31st March, 2020</b>	<b>59.90</b>	<b>544.87</b>	<b>49.62</b>	<b>3,073.16</b>	<b>95.14</b>	<b>8.63</b>	<b>2.08</b>	<b>1.14</b>	<b>3,834.54</b>	<b>0.00</b>
<b>Accumulated depreciation:</b>										
As at 31st March, 2019	-	188.64	44.07	1,313.66	46.30	0.98	0.69	0.50	1,594.85	0.00
Depreciation charged during the year	-	16.47	0.85	138.54	4.41	1.28	0.08	0.04	161.65	0.00
Disposals / transfers	-	-	-	-	-	-	-	-	-	0.00
<b>As at 31st March, 2020</b>	<b>-</b>	<b>205.11</b>	<b>44.92</b>	<b>1,452.20</b>	<b>50.71</b>	<b>2.25</b>	<b>0.77</b>	<b>0.54</b>	<b>1,756.50</b>	<b>0.00</b>
<b>Net book value</b>										
As at 31st March, 2019	59.90	355.51	5.03	1,644.01	46.33	7.65	1.39	0.45	2,120.26	-
<b>As at 31st March, 2020</b>	<b>59.90</b>	<b>339.76</b>	<b>4.71</b>	<b>1,620.96</b>	<b>44.43</b>	<b>6.37</b>	<b>1.31</b>	<b>0.60</b>	<b>2,078.04</b>	<b>0.00</b>

**DINESH REMEDIES LIMITED****STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 31st MARCH, 2020****(A) EQUITY SHARE CAPITAL**

For the year ended 31st March, 2020

(Rs. In Lakhs)

Balance as at 1st April, 2019	Changes during the year	Balance as at 31st March, 2020
2,359.16	-	2,359.16

For the year ended 31st March, 2019

(Rs. In Lakhs)

Balance as at 1st April, 2018	Changes during the year	Balance as at 31st March, 2019
2,359.16	-	2,359.16

**(B) OTHER EQUITY**

For the year ended 31st March, 2020

Particulars	Retained Earnings	FVOCI Reserve	Total Equity
Balance as at 1st April, 2019	(540.13)	2.84	(537.29)
Profit/(Loss) for the year	(80.21)	-	(80.21)
Other Comprehensive income/(loss) for the year	-	-	-
Remeasurements gain/(loss) on defined benefit plans	-	(2.61)	(2.61)
<b>Balance as at 31st March, 2020</b>	<b>(620.34)</b>	<b>0.23</b>	<b>(620.12)</b>

For the year ended 31st March, 2019

Particulars	Retained Earnings	FVOCI Reserve	Total Equity
Balance as at 1st April, 2018	(495.06)	3.44	(491.62)
Profit/(Loss) for the year	(45.07)	-	(45.07)
Transfer from / to	-	-	-
Other Comprehensive income/(loss) for the year	-	-	-
Remeasurements gain/(loss) on defined benefit plans	-	(0.60)	(0.60)
<b>Balance as at 31st March, 2019</b>	<b>(540.13)</b>	<b>2.84</b>	<b>(537.29)</b>

"As per our report of even date attached"

**ON BEHALF OF THE BOARD OF DIRECTORS****For DHIRUBHAI SHAH & CO LLP**

Chartered Accountants

Firm Registration Number: 102511W/W100298

Chairman &amp; Managing

Director

Director

**Harish B Patel**

Partner

Membership Number: 014427

Place: Vadodara

Dated : 25th June, 2020

Chief Financial Officer

Company Secretary

**DINESH REMEDIES LIMITED**  
**NOTES ANNEXED TO AND FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2020**

	As at 31-03-2020 (Rs. In Lakhs)	As at 31-03-2019 (Rs. In Lakhs)
<b>5 - NON - CURRENT FINANCIAL ASSETS - LOANS</b>		
Unsecured, considered good, unless otherwise stated		
Security deposits	28.92	37.56
	<b>28.92</b>	<b>37.56</b>

**Allowance for Doubtful Loans**

Company has analysed any allowance for doubtful loans based on the 12 months expected credit loss model.

	As at 31-03-2020 (Rs. In Lakhs)	As at 31-03-2019 (Rs. In Lakhs)
<b>6 - NON - CURRENT ASSETS - OTHERS</b>		
Other Assets		
- Gratuity Fund	11.18	14.50
	<b>11.18</b>	<b>14.50</b>

	As at 31-03-2020 (Rs. In Lakhs)	As at 31-03-2019 (Rs. In Lakhs)
<b>7 - INVENTORIES</b>		
(valued at lower of cost and net realizable value)		
Raw Material	53.83	153.61
Work in Progress	62.42	50.45
Finished Goods	71.90	42.25
Consumable Stores and Spares	20.40	21.20
Others	11.11	17.32
	<b>219.67</b>	<b>284.83</b>

- As per inventory taken and valued by the Management

	As at 31-03-2020 (Rs. In Lakhs)	As at 31-03-2019 (Rs. In Lakhs)
<b>8 - TRADE RECEIVABLES</b>		
Unsecured		
Other debts		
Considered good	459.30	618.98
Considered doubtful	-	-
	<b>459.30</b>	<b>618.98</b>
Less: Provision for doubtful debts	-	-
	<b>459.30</b>	<b>618.98</b>

**Allowance for Doubtful Debts**

Company has analysed any allowance for doubtful debts based on the lifetime expected credit loss model. - Refer Note - 34

	As at 31-03-2020 (Rs. In Lakhs)	As at 31-03-2019 (Rs. In Lakhs)
<b>9 - CASH AND CASH EQUIVALENTS</b>		
Balances with banks		
In current accounts	32.22	4.89
Cash in hand	0.56	0.37
	<b>32.78</b>	<b>5.26</b>

	As at 31-03-2020 (Rs. In Lakhs)	As at 31-03-2019 (Rs. In Lakhs)
<b>10 - CURRENT ASSETS - OTHERS</b>		
<b>Unsecured, considered good, unless otherwise stated</b>		
Others		
Prepaid expenses	2.70	2.07
Balance with statutory authorities	3.76	22.88
Advances to Trade Payables	5.42	14.25
Others	1.39	8.92
	<b>13.27</b>	<b>48.11</b>

	As at 31-03-2020 (Rs. In Lakhs)	As at 31-03-2019 (Rs. In Lakhs)
<b>11 - SHARE CAPITAL</b>		
<b>Authorised:</b>		
2,50,00,000 (March 31, 2019: 2,50,00,000) Equity Shares of Rs. 10 each	2,500.00	2,500.00
<b>Issued, Subscribed and paid-up:</b>		
2,35,91,580 (March 31, 2019: 2,35,91,580) Equity Shares of Rs. 10 each fully paid up	2,359.16	2,359.16
	<b>2,359.16</b>	<b>2,359.16</b>

#### 11.1. Reconciliation of shares outstanding at the beginning and at the end of the Reporting year

Particulars	As at 31-03-2020		As at 31-03-2019	
	No. of Shares	(Rs. In Lakhs)	No. of Shares	(Rs. In Lakhs)
At the beginning of the year	2,35,91,580	23,59,15,800	2,35,91,580	23,59,15,800
Add: Shares issued during the year	-	-	-	-
Shares outstanding at the end of the year	<b>2,35,91,580</b>	<b>23,59,15,800</b>	<b>2,35,91,580</b>	<b>23,59,15,800</b>

#### 11.2. Terms/Rights attached to the equity shares

The Company has one class of shares referred to as equity shares having a par value of Rs. 10 each. Each shareholder is entitled to one vote per share held. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting. In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the Company after distribution of all preferential amounts, in proportion to their shareholding.

#### 11.3. Number of Shares held by each shareholder holding more than 5% Shares in the company

Name of Shareholder	As at 31-03-2020		As at 31-03-2019	
	No. of Shares	% of Holding	No. of Shares	% of Holding
Shri Dinesh Mills Ltd.	1,30,98,095	55.52	1,30,98,095	55.52
Shri Rashmikant C. Patel	31,39,715	13.31	31,39,715	13.31
Star Capsules LLC, USA (OCB)	73,53,765	31.17	73,53,765	31.17
	<b>2,35,91,575</b>	<b>100</b>	<b>2,35,91,575</b>	<b>100.00</b>

	As at 31-03-2020 (Rs. In Lakhs)	As at 31-03-2019 (Rs. In Lakhs)
<b>12 - OTHER EQUITY</b>		
<b>Surplus in Statement of Profit and Loss</b>		
Opening balance	(540.13)	(495.06)
Profit / (loss) during the year	(80.21)	(45.07)
Closing balance	<b>(620.34)</b>	<b>(540.13)</b>
<b>Fair Value through Other Comprehensive Income [FVTOCI] Reserve</b>		
Opening balance	2.84	3.44
Adjusted from surplus in statement of profit and loss		
- Re-measurement gains / (losses) on employee benefits	(2.61)	(0.60)
	<b>0.23</b>	<b>2.84</b>
<b>Total of other equity</b>	<b>(620.12)</b>	<b>(537.29)</b>

	As at 31-03-2020 (Rs. In Lakhs)	As at 31-03-2019 (Rs. In Lakhs)
<b>13 - NON - CURRENT FINANCIAL LIABILITIES - BORROWINGS</b>		
<b>Secured Term Loans</b>		
<b>From Banks</b>		
Other Term Loans	151.32	366.49
Less: Current Maturities of Long Term Debt	(20.50)	(174.39)
	<b>130.83</b>	<b>192.10</b>

#### a. Nature of Security

The loans are secured by exclusive and specific charge created on Fixed Assets

#### b. Rate of Interest and Terms of Repayment

Name of Institution	Instruments	Starting From	Frequency	Repayment Schedule		
				Frequency	Rate of Interest	First Installment due
South Indian Bank Ltd	Term Loan - 541	Dec-11	Monthly	Monthly	10.50%	15 March 2014
South Indian Bank Ltd	Term Loan - 40L	Sep-18	Monthly	Monthly	10.75%	14 April 2019
South Indian Bank Ltd	Term Loan - 40L	Apr-19	Monthly	Monthly	10.40%	06-Nov-19
South Indian Bank Ltd	Term Loan - 63.50L	Nov-19	Monthly	Monthly	10.15%	10-Dec-19

	As at 31-03-2020 (Rs. In Lakhs)	As at 31-03-2019 (Rs. In Lakhs)
<b>14 - NON - CURRENT PROVISIONS</b>		
Provision for employee benefit		
Gratuity	16.54	18.81
Leave Encashment	7.00	6.13
	<b>23.54</b>	<b>24.94</b>

	As at 31-03-2020	As at 31-03-2019
<b>15 - CURRENT FINANCIAL LIABILITIES - BORROWINGS</b>		
<b>Secured</b>		
(a) Loans repayable on demand		
- from banks	421.39	244.07
	<b>421.39</b>	<b>244.07</b>

**a. Nature of Security**

(Working capital loans are secured by hypothecation of present and future stock of raw materials, stock-in-process, finished goods, stores and spares, book debts, material in transit, etc.). Rate of interest of the captioned loan is 10%.

	As at 31-03-2020 (Rs. In Lakhs)	As at 31-03-2019 (Rs. In Lakhs)
<b>16 - CURRENT FINANCIAL LIABILITIES - TRADE PAYABLES</b>		
Due to micro and small enterprises	16.16	12.99
Due to other than micro and small enterprises	444.46	608.89
	<b>460.62</b>	<b>621.88</b>

**a. Disclosure under Section 22 of Micro, Small and Medium Enterprise Development (MSMED) Act, 2006**

The Company has received intimation from certain number of

( a ) Principal amount and the interest due thereon remaining unpaid to any suppliers as at the end of accounting year;	16.16	12.99
( b ) Interest paid during the year	-	-
( c ) Amount of payment made to the supplier beyond the	-	-
( d ) Interest due and payable for the period of delay in making payment;	-	-
( e ) Interest accrued and unpaid at the end of the accounting year; and	-	-
( f ) Further interest remaining due and payable even in the succeeding years, until such date when the interest dues above are actually paid to the small enterprise; have not been given.	-	-

The outstanding to MSME is calculated based on the information available with the company

	As at 31-03-2020 (Rs. In Lakhs)	As at 31-03-2019 (Rs. In Lakhs)
<b>17 - CURRENT - OTHER FINANCIAL LIABILITIES</b>		
Current Maturities of Long Term Debts	20.50	174.39
Other Liabilities #	30.07	33.26
	<b>50.56</b>	<b>207.65</b>

a. There are no amounts due for payment to the Investor Education and Protection Fund under Section 125 of the Companies Act, 2013 as on March 31, 2020 (March 31, 2019: Nil).

# Other liabilities includes staff payable and bonus

	As at 31-03-2020 (Rs. In Lakhs)	As at 31-03-2019 (Rs. In Lakhs)
<b>18 - OTHER CURRENT LIABILITIES</b>		
Advance from customers	3.79	9.78
Statutory liabilities	3.79	4.67
	<b>7.57</b>	<b>14.44</b>

	As at 31-03-2020 (Rs. In Lakhs)	As at 31-03-2019 (Rs. In Lakhs)
<b>19 - SHORT TERM PROVISIONS</b>		
Provision for employee benefit		
Gratuity	6.92	1.34
Leave Encashment	2.69	1.22
	<b>9.60</b>	<b>2.56</b>

	2019-20	2018-19
	(Rs. In Lakhs)	(Rs. In Lakhs)
<b>20 - REVENUE FROM OPERATIONS</b>		
Sale of Products	1,934.69	2,065.70
	<b>1,934.69</b>	<b>2,065.70</b>

	2019-20	2018-19
	(Rs. In Lakhs)	(Rs. In Lakhs)
<b>21 - OTHER INCOME</b>		
Interest Received/Receivable		
From banks	2.20	2.38
Net gain on foreign currency transaction and translation	4.68	0.59
Duty Drawback and Other Export Incentives	9.04	19.75
Miscellaneous income	0.92	1.77
Scarp Sale	0.27	-
	<b>17.11</b>	<b>24.49</b>

	2019-20	2018-19
	(Rs. In Lakhs)	(Rs. In Lakhs)
<b>22 - COST OF MATERIALS CONSUMED</b>		
<b>GELATINE &amp; OTHERS</b>		
Opening Stock	153.61	30.50
Add : Purchases	800.89	1,037.63
	<b>954.50</b>	<b>1,068.13</b>
Closing Stock	(53.83)	(153.61)
	<b>900.67</b>	<b>914.53</b>
	<b>900.67</b>	<b>914.53</b>

	2019-20	2018-19
	(Rs. In Lakhs)	(Rs. In Lakhs)
<b>23 - CHANGES IN INVENTORIES OF FINISHED GOODS, STOCK-IN-TRADE AND WORK IN PROGRESS</b>		
<b>Inventories (at close):</b>		
Work -in- Process	62.42	50.45
Finished Goods	71.90	42.25
	<b>134.32</b>	<b>92.70</b>
<b>Inventories (at commencement):</b>		
Work -in- Process	50.45	41.75
Finished Goods	42.25	42.83
	<b>92.70</b>	<b>84.58</b>
<b>Total</b>	<b>(41.63)</b>	<b>(8.12)</b>

	2019-20	2018-19
	(Rs. In Lakhs)	(Rs. In Lakhs)
<b>24 - EMPLOYEE BENEFITS EXPENSES</b>		
Salaries and wages	310.22	316.69
Contribution to provident and other funds	16.93	12.26
Staff Welfare Expense	0.71	0.18
	<b>327.86</b>	<b>329.13</b>

	2019-20	2018-19
	(Rs. In Lakhs)	(Rs. In Lakhs)
<b>25 - FINANCE COSTS</b>		
Interest expenses	57.24	54.76
Other borrowing costs (including bank charges)	3.74	4.29
	<b>60.98</b>	<b>59.06</b>

<b>26 - OTHER EXPENSES</b>	<b>2019-20</b>	<b>2018-19</b>
	<b>(Rs. In Lakhs)</b>	<b>(Rs. In Lakhs)</b>
<b>OPERATING, ADMINISTRATION AND GENERAL EXPENSES</b>		
Stores, Spares and Packing Materials	86.33	93.76
Electricity, Power and Fuel	325.92	326.11
Repairs, maintenance and refurbishing *	32.47	39.41
Rates and taxes	1.02	0.94
Insurance	6.84	13.99
Legal and professional charges	4.97	7.93
Payment to the auditors**	0.97	0.84
Freight Outward	64.32	61.66
Commission and brokerage	11.11	26.80
Miscellaneous	88.52	113.39
	<b>622.48</b>	<b>684.83</b>
* includes:		
Repairs to buildings	2.41	1.54
Repairs to machinery	30.06	37.87
**Payments to the auditors for		
-statutory audit	0.84	0.70
-tax audit fee	0.13	0.13
-out of pocket expenses	-	0.01
	<b>0.97</b>	<b>0.84</b>

<b>27 - EARNINGS PER EQUITY SHARE</b>	<b>2019-20</b>	<b>2018-19</b>
	<b>(Rs. In Lakhs)</b>	<b>(Rs. In Lakhs)</b>
Profit/(loss) available for equity shareholders	<b>(80.21)</b>	(45.07)
Weighted average numbers of equity shares outstanding	<b>2,35,91,580</b>	2,35,91,580
Nominal value per equity share (in Rupees)	<b>10.00</b>	10.00
<b>Earnings /(loss) Per Equity Share- Basic and Diluted (in Rupees)</b>	<b>(0.34)</b>	<b>(0.19)</b>

**DINESH REMEDIES LIMITED**

NOTES ANNEXED TO AND FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31st MARCH, 2020

	As at 31-03-2020 (Rs. In Lakhs)	As at 31-03-2019 (Rs. In Lakhs)
<b>28 - CONTINGENT LIABILITIES AND COMMITMENTS</b>		
<b>CONTINGENT LIABILITIES</b>		
(a) Arrears of Bonus to employees for FY 2014-15, as amended by Factories Act, not provided for	1.66	1.66
<b>Notes:</b>		
(a) It is not practicable to estimate the timing of cash outflows, if any, in respect of matters stated above, pending resolution of the proceedings.		
<b>COMMITMENTS</b>		
NIL		

**29 - SEGMENT REPORTING**

The Company has only one primary business segment viz. Pharmaceutical business and operates only within India and hence the disclosure as required under Ind-AS 108 on "Operating Segments" is not required.

**30 - DISCLOSURES AS REQUIRED BY INDIAN ACCOUNTING STANDARD (IND AS) 19 EMPLOYEE BENEFITS**

The Company has classified the various benefits provided to employees as under:-

**(a) Defined contribution plans**

-Provident fund

The Company has recognized the following amounts in the statement of profit and loss:

Employers' contribution to provident fund :- Current Year Rs. 16.93 Lakhs (Previous Year Rs. 12.26 Lakhs)

**(b) Defined benefit plans**

- Gratuity

In accordance with Indian Accounting Standard 19, actuarial valuation was done in respect of the aforesaid defined benefit plans based on the following assumptions-

**Economic Assumptions**

The discount rate and salary increases assumed are the key financial assumptions and should be considered together; it is the difference or 'gap' between these rates which is more important than the individual rates in isolation.

**Discount Rate**

The discounting rate is based on the gross redemption yield on medium to long term risk free investments. The estimated term of the benefits/obligations works out to zero years. For the current valuation a discount rate of 6.85% p.a. (Previous Year 7.79% p.a.) compound has been used.

**Salary Escalation Rate**

The salary escalation rate usually consists of at least three components, viz. regular increments, price inflation and promotional increases. In addition to this any commitments by the management regarding future salary increases and the Company's philosophy towards employee remuneration are also to be taken into account. Again a long-term view as to trend in salary increase rates has to be taken rather than be guided by the escalation rates experienced in the immediate past, if they have been influenced by unusual factors.



The assumptions used are summarized in the following table:

	Gratuity (Unfunded)	
	As at 31-03-2020 (Rs. In Lakhs)	As at 31-03-2019 (Rs. In Lakhs)
<b>Change in present value of the defined benefit obligation during the year</b>		
Present value of obligation as at the beginning of the year	20.15	16.26
Interest Cost	1.57	1.28
Current Service Cost	2.96	2.73
Benefits Paid	-3.42	-0.76
Actuarial (Gain)/Loss on arising from Change in Demographic Assumption	2.93	0.00
Actuarial (Gain)/Loss on arising from Change in Financial Assumption	1.47	0.12
Actuarial (Gain)/Loss on arising from Experience Adjustment	-2.20	0.53
Present value of obligation as at the end of the year	23.46	20.15
<b>Change in fair value of plan assets during the year</b>		
Fair Value of plan assets at the beginning of the year	18.81	13.76
Interest Income	1.47	1.08
Contributions by the employer	0.10	4.68
Benefits paid	-3.42	-0.76
Return on plan assets	-0.41	0.05
Fair Value of plan assets at the end of the year	16.54	18.81
<b>Net Asset/ (Liability) recorded in the Balance Sheet</b>		
Present value of obligation as at the end of the year	23.46	20.15
Net Asset/ (Liability)-Current	6.92	1.34
Net Asset/ (Liability)-Non-Current	16.54	18.81
<b>Expenses recorded in the Statement of Profit &amp; Loss during the year</b>		
Net Interest Cost	1.16	1.33
Current Service Cost	2.96	2.73
Total expenses included in employee benefit expenses	4.11	4.05
<b>Recognized in Other Comprehensive Income during the year</b>		
Actuarial (Gain)/Loss on arising from Change in Financial Assumption	2.61	0.60
<b>Maturity profile of defined benefit obligation</b>		
1st following year	4.44	3.98
2nd following year	2.78	0.51
3rd following year	3.11	1.50
4th following year	2.76	1.18
5th year and thereafter	19.52	45.54
<b>Quantitative sensitivity analysis for significant assumption is as below:</b>		
Increase/ (decrease) on present value of defined benefit obligation at the end of the year		
1 percentage point increase in discount rate	-0.98	-1.63
1 percentage point decrease in discount rate	1.08	1.93
1 percentage point increase in salary increase rate	1.08	1.97
1 percentage point decrease in salary increase rate	-1.00	-1.68

**31 - HEDGED AND UNHEDGED DERIVATIVE INSTRUMENTS**

(a) The amount of foreign currency exposures that are not hedged by a derivative instrument or otherwise as at 31st March, 2020 are as under:

	As at 31st March, 2020		As at 31st March, 2019	
	Foreign Currency	(Rs. In Lakhs)	Foreign Currency	(Rs. In Lakhs)
<b>Receivables</b>				
Trade Receivables (in USD)	<b>38,643.58</b>	<b>29,10,828</b>	3,26,603.32	2,26,59,673
<b>Payables</b>				
Trade payables (in USD)	-	-		

**DINESH REMEDIES LIMITED**

NOTES ANNEXED TO AND FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31st MARCH, 2020

**32 - RELATED PARTY DISCLOSURES AS PER INDIAN ACCOUNTING STANDARD-24****(a) Related Parties****i) Holding Company**

- Shree Dinesh Mills Limited

**ii) Key Managerial Personnel**

<b>Name</b>	<b>Relationship/Designation</b>
Mr. N. U. Patel	Chairman & Managing Director
Mr. Bindesh Patel	Chief Financial Officer
Mr. Shrihari Shukla	Company Secretary

**(b) Transactions with related parties:**

	<b>Total</b>			
	<b>2019-20</b> <b>(Rs. In Lakhs)</b>	<b>2018-19</b> <b>(Rs. In Lakhs)</b>	<b>2019-20</b> <b>(Rs. In Lakhs)</b>	<b>2018-19</b> <b>(Rs. In Lakhs)</b>
Director's Sitting fees	50,000	77,000	<b>50,000</b>	77,000
Remuneration paid to Chief Financial Officer	6,35,000	6,00,000	<b>6,35,000</b>	6,00,000
Remuneration paid to Company Secretary	1,02,000	1,02,000	<b>1,02,000</b>	1,02,000

**33. FINANCIAL INSTRUMENTS - ACCOUNTING CLASSIFICATIONS AND FAIR VALUE MEASUREMENTS**

The fair values of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.

The following methods and assumptions were used to estimate the fair values:

1. Fair values of cash and short term deposits, trade and other short term receivables, trade payables, other current liabilities, short term loans from banks and other financial institutions approximate their carrying amounts largely due to short-term maturities of these instruments.
2. Financial instruments with fixed and variable interest rates are evaluated by the Company based on parameters such as interest rates and individual credit worthiness of the counterparty. Based on the evaluation, allowances are taken to account for the expected losses of these receivables.

The company uses the following hierarchy for determining and disclosing the fair values of financial instruments by valuation technique:

Level 1 : Quoted (unadjusted) prices in active markets for identical assets or liabilities.

Level 2 : Other techniques for which all inputs which have a significant effects on the recorded fair value are observable, either directly or indirectly.

Level 3 : Techniques which use inputs that have a significant effects on the recorded fair value that are not based on observable market data.

**I. Figures as at March 31, 2020**

Financial Instrument	Note No.	Carrying Amount					Fair value			
		FVTPL	FVOCI	Total Fair Value	Amortised Cost	Total	Level 1	Level 2	Level 3	Total
<b>Non Current Assets</b>										
<b>Financial Assets</b>										
(i) Loans	5	-	-	-	28.92	28.92	-	-	-	-
<b>Current Assets</b>										
<b>Financial Assets</b>										
(i) Trade Receivables	8	-	-	-	459.30	459.30	-	-	-	-
(ii) Cash and Cash Equivalents	9	-	-	-	32.78	32.78	-	-	-	-
		-	-	-	<b>521.00</b>	<b>521.00</b>	-	-	-	-
<b>Non Current Liabilities</b>										
<b>Financial Liabilities</b>										
(i) Borrowings	13	-	-	-	130.83	130.83	-	-	-	-
<b>Current Liabilities</b>										
<b>Financial Liabilities</b>										
(i) Borrowings	15	-	-	-	421.39	421.39	-	-	-	-
(ii) Trade Payables	16	-	-	-	460.62	460.62	-	-	-	-
(iii) Other Financial Liabilities	17	-	-	-	50.56	50.56	-	-	-	-
		-	-	-	<b>1,063.42</b>	<b>1,063.42</b>	-	-	-	-

**II. Figures as at March 31, 2019**

Financial Instrument	Note No.	Carrying Amount					Fair value			
		FVTPL	FVOCI	Total Fair Value	Amortised Cost	Total	Level 1	Level 2	Level 3	Total
<b>Non Current Assets</b>										
<b>Financial Assets</b>										
(i) Loans	5	-	-	-	37.56	37.56	-	-	-	-
<b>Current Assets</b>										
<b>Financial Assets</b>										
(i) Trade Receivables	8	-	-	-	618.98	618.98	-	-	-	-
(ii) Cash and Cash Equivalents	9	-	-	-	5.26	5.26	-	-	-	-
		-	-	-	<b>661.80</b>	<b>661.80</b>	-	-	-	-
<b>Non Current Liabilities</b>										
<b>Financial Liabilities</b>										
(i) Borrowings	13	-	-	-	192.10	192.10	-	-	-	-
<b>Current Liabilities</b>										
<b>Financial Liabilities</b>										
(i) Borrowings	15	-	-	-	244.07	244.07	-	-	-	-
(ii) Trade Payables	16	-	-	-	621.88	621.88	-	-	-	-
(iii) Other Financial Liabilities	17	-	-	-	207.65	207.65	-	-	-	-
		-	-	-	<b>1,265.71</b>	<b>1,265.71</b>	-	-	-	-

During the reporting period ending March 31, 2020 and March 31, 2019, there were no transfers between Level 1 and Level 2 fair value measurements.

**34. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES**

The Company's financial risk management is an integral part of how to plan and execute its business strategies.

**Market risk**

Market risk is the risk of loss of future earnings, fair values or future cash flows that may result from a change in the price of a financial instrument. The value of a financial instrument may change as a result of changes in the interest rates, foreign currency exchange rates, equity prices and other market changes that affect market risk sensitive instruments. Market risk is attributable to all market risk sensitive financial instruments including investments and deposits, foreign currency receivables, payables and loan borrowings.

The Company is expecting to derive a good part of its revenues from outside India. Within India, the Company' have an extensive marketing network and goodwill among the customers. The Company is optimistic that with its quality product and good customer relations will enable it to enhance its presence in its chosen markets. The Company is concentrating on serving a rationalized customer base in the domestic market accompanied by higher satisfaction and retention levels as an effective counter to the new entrant in the business.

**Interest rate risk**

Interest rate risk is the risk that fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. In order to optimize the company's position with regards to the interest income and interest expenses and to manage the interest rate risk, treasury performs a comprehensive corporate interest rate risk management by balancing the proportion of fixed rate and floating rate financial instruments in its total portfolio.

The company is not exposed to significant interest rate risk as at the specified reporting date on account absence of any instruments whose interest rate is dependent on foreign exchange fluctuation.

Refer Note 13 and 15 for interest rate profile of the Company's interest-bearing financial instrument at the reporting date.

**Foreign currency risk**

The Company operates in domestic as well as international market, however, the nature of its operations requires it to transact in several currencies and consequently the Company is exposed to foreign exchange risk in various foreign currencies. In current year about 25 % of the Company's revenue from capsules is from export. The Company has laid down procedures to de-risk itself against currency volatility and out sources expert advice whenever required.

The Company evaluates exchange rate exposure arising from foreign currency transactions and the Company follows established risk management policies.

**I. Foreign Currency Exposure**

Refer Note 31 for foreign currency exposure as at March 31, 2020, and March 31, 2019 respectively.

**II. Foreign Currency Sensitivity**

1% increase or decrease in foreign exchange rates will have the following impact on the profit before tax

Currency	2019-20		2018-19	
	1% Increase	1% Decrease	1% Increase	1% Decrease
INR	0.29	(0.29)	5.58	(5.58)
<b>Total</b>	<b>0.29</b>	<b>(0.29)</b>	<b>5.58</b>	<b>(5.58)</b>

**Credit risk**

Credit risk arises from the possibility that counter party may not be able to settle their obligations as agreed. To manage this, the Company periodically assesses the financial reliability of customers, taking into account the financial condition, current economic trends, and analysis of historical bad debts and ageing of accounts receivable. Individual risk limits are set accordingly.

The Company considers the probability of default upon initial recognition of asset and whether there has been a significant increase in credit risk on an ongoing basis throughout each reporting period. To assess whether there is significant increase in credit risk the company compares the risk of a default occurring on the asset at the reporting date with the risk of default as the date of initial recognition. It considers reasonable and supportive forwarding-looking information such as:

- (i) Actual or expected significant adverse changes in business,
- (ii) Actual or expected significant changes in the operating results of the counterparty.
- (iii) Financial or economic conditions that are expected to cause a significant change to the counterparty's ability to meet its obligation,
- (iv) Significant increase in credit risk on other financial instruments of the same counterparty.
- (v) Significant changes in the value of the collateral supporting the obligation or in the quality of third-party guarantees or credit enhancements.

Financial assets are written off when there is no reasonable expectation of recovery, such as a debtor failing to engage in a repayment plan with the Company. The Company categorises a loan or receivable for write off when a debtor fails to make contractual payments greater than reasonable period of time decided by the Management. Where loans or receivables have been written off, the Company continues to engage in enforcement activity to attempt to recover the receivable due. Where recoveries are made, these are recognised in profit or loss.

**DINESH REMEDIES LIMITED**

**NOTES ANNEXED TO AND FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31st MARCH, 2020**

**34. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (Contd.)**

**I. Financial assets for which loss allowance is measured using 12 months Expected Credit Losses (ECL)**

Particulars	As at	As at
	31-03-2020	31-03-2019
Non-current financial assets - Loans	28.92	37.56
Current financial assets - loans	-	-
<b>Total (A)</b>	<b>28.92</b>	<b>37.56</b>

**II. Financial assets for which loss allowance is measured using 12 months Life Time Expected Credit Losses (ECL)**

Particulars	As at	As at
	31-03-2020	31-03-2019
Trade Receivables	459.30	618.98
<b>Total (A)</b>	<b>459.30</b>	<b>618.98</b>

**Grand Total (A+B)**

Balances with banks are subject to low credit risks due to good credit ratings assigned to these banks.

**III. The ageing analysis of these receivables (gross of provision) has been considered from the date the invoice falls due**

Particulars	As at	As at
	31-03-2020	31-03-2019
Up to 6 months	383.50	501.85
More than 6 months	75.80	117.13
<b>Total</b>	<b>459.30</b>	<b>618.98</b>

**IV. Provision for expected credit losses against "II" and "III" above**

The company has assets where the counter- parties have sufficient capacity to meet the obligations and where the risk of default is very low. Hence based on historic default rates, the Company believes that, no impairment allowance is necessary in respect of above mentioned financial assets.

**Liquidity Risk**

Liquidity Risk is defined as the risk that the company will not be able to settle or meet its obligations on time or at reasonable price. The company is responsible for liquidity, funding as well as settlement management. In addition, processes and policies related to such risks are overseen by senior management. Management monitors the company's net liquidity position through rolling forecast on the basis of expected cash flows.

*Maturity profile of financial liabilities*

The table below provides details regarding the remaining contractual maturities of financial liabilities at the reporting date based on contractual undiscounted payments.

Particulars	As at 31-03-2020				As at 31-03-2019		
	Less than 1 year	1 to 5 years	More than 5 Years	Total	Less than 1 year	1 to 5 years	Total
Non-current financial liabilities - Borrowings	20.50	119.87	10.96	151.32	174.39	181.14	355.53
Current financial liabilities - Borrowings	421.39	-	-	421.39	244.07	-	244.07
Current financial liabilities - Trade Payables	460.62	-	-	460.62	621.88	-	621.88
Current financial liabilities - Others	50.56	-	-	50.56	207.65	-	207.65
<b>Total</b>	<b>953.08</b>	<b>119.87</b>	<b>10.96</b>	<b>1,083.91</b>	<b>1,247.98</b>	<b>181.14</b>	<b>1,429.12</b>

**Capital management**

For the purposes of the Company's capital management, capital includes issued capital and all other equity reserves. The primary objective of the Company's Capital Management is to maximise shareholder value. The company manages its capital structure and makes adjustments in the light of changes in economic environment and the requirement of the financial covenants.

The company monitors capital using gearing ratio, which is total debt divided by total capital plus debt.

Particulars	As at	As at
	31-03-2020	31-03-2019
Total Debt	552.22	436.17
Equity	1,739.04	1,821.87
<b>Capital and net debt</b>	<b>2,291.26</b>	<b>2,258.04</b>
<b>Gearing ratio</b>	<b>24.10%</b>	<b>19.32%</b>

**DINESH REMEDIES LIMITED**  
**NOTES ANNEXED TO AND FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31ST MARCH, 2020**

**1. CORPORATE INFORMATION**

Dinesh Remedies Ltd. (DRL) has been manufacturing high quality two-piece hard gelatin capsules for the pharmaceutical and dietary supplement markets. The company's focus on continual process improvement and product innovation is backed by state-of-the-art infrastructure and a team of highly skilled and knowledgeable scientists, pharmacists and researchers.

**2. BASIS OF PREPARATION AND SIGNIFICANT ACCOUNTING POLICIES**

a) Basis of preparation

In accordance with the notification issued by the Ministry of Corporate Affairs, the Company has adopted Ind AS notified under the Companies (Indian Accounting Standards) Rules, 2015 with effect from April 1, 2017.

b) Functional and presentation currency

These financial statements are presented in Indian rupee, which is the Company's functional currency. All amounts have been rounded to the nearest lakh, unless otherwise indicated.

c) Basis of measurement

The financial statements have been prepared on historical cost basis, except certain financial assets and liabilities which have been measured at fair value (refer accounting policy regarding financial instruments), defined benefits plans - plan assets and contingent consideration. The accounting policies have been consistently applied by the Company and are consistent with those used in the previous year.

All assets and liabilities have been classified as current or non-current as per the Company's normal operating cycle and other criteria set out in the Schedule III to the Act. Based on the nature of products and the time between acquisition of assets for processing and their realization in cash and cash equivalents, the Company has ascertained its operating cycle as 12 months for the purposes of current / non-current classification of assets and liabilities.

**Current versus non-current classification**

The Company presents assets and liabilities in the balance sheet based on current/ non-current classification.

An asset is treated as current when it is:

- a. Expected to be realized or intended to be sold or consumed in normal operating cycle
- b. Held primarily for the purpose of trading
- c. Expected to be realized within twelve months after the reporting period, or
- d. Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period

All other assets are classified as non-current.

A liability is current when:

- a. It is expected to be settled in normal operating cycle
- b. It is held primarily for the purpose of trading
- c. It is due to be settled within twelve months after the reporting period, or
- d. There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period



**DINESH REMEDIES LIMITED**  
**NOTES ANNEXED TO AND FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31ST MARCH, 2020**

All other liabilities are classified as non-current.  
Deferred tax assets and liabilities are classified as non-current assets and liabilities.

## **2A. USE OF ESTIMATES**

The preparation of financial statements requires the use of accounting estimates which, by definition, will seldom equal the actual results. Management also needs to exercise judgment in applying the group's accounting policies. This note provides an overview of the areas that involved a higher degree of judgment or complexity, and of items which are more likely to be adjusted due to estimates and assumptions turning out to be different from those originally assessed. Detailed information about each of these estimates and judgments is included in relevant notes together with information about the basis of calculation for each affected line item in the financial statements.

### Critical estimates and judgments

The areas involving critical estimates or judgments are:

- a) Estimation of current tax expense and payable – Refer accounting policies - 3.9
- b) Estimated useful life of property, plant & equipment and intangible assets – Refer accounting policies - 3.1
- c) Estimation of defined benefit obligation – Refer accounting policies - 3.8
- d) Estimation of fair values of contingent liabilities - Refer accounting policies - 3.12
- e) Recognition of revenue - Refer accounting policies - 3.4
- f) Recognition of deferred tax assets for carried forward tax losses – Refer accounting policies - 3.9
- g) Impairment of financial assets – Refer accounting policies - 3.2 & 3.5

Estimates and judgments are continually evaluated. They are based on historical experience and other factors, including expectations of future events that may have a financial impact on the group and that are believed to be reasonable under the circumstances.

## **3. SIGNIFICANT ACCOUNTING POLICIES**

### **3.1 Property, plant and equipment:**

Property, plant and equipment are stated at original cost net of tax / duty credit availed, less accumulated depreciation and accumulated and accumulated impairment losses, if any. Costs include financing costs of borrowed funds attributable to acquisition or construction of fixed assets, up to the date the assets are put-to-use.

When significant parts of property, plant and equipment are required to be replaced at intervals, the Company derecognizes the replaced part, and recognizes the new part with its own associated useful life and it is depreciated accordingly. Where components of an asset are significant in value in relation to the total value of the asset as a whole, and they have substantially different economic lives as compared to principal item of the asset, they are recognized separately as independent items and are depreciated over their estimated economic useful lives.

All other repair and maintenance costs are recognized in the statement of profit and loss as incurred unless they meet the recognition criteria for capitalization under Property, Plant and Equipment

### Tangible Fixed Assets:

- (a) Depreciation on all the assets is being provided on straight line method in accordance with the provisions of section 123 of the Companies Act, 2013 considering the useful life provided in

**DINESH REMEDIES LIMITED**  
**NOTES ANNEXED TO AND FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31ST MARCH, 2020**

part "C" of the schedule II. The useful life of Continuous process plants and electrical installations are considered based on the technical assessment by the management (20 years' life is considered).

- (b) Depreciation on additions to the assets during the year is being provided on pro rata basis at their respective rates derived from useful life from the date of such addition or as the case may be as provided in section 123 of the Companies Act, 2013. On transition to Ind AS as on April 1, 2016, the Company has elected to measure its Property, Plant and Equipment at cost as per Ind AS.

Capital Work- in- progress

Capital work- in- progress represents directly attributable costs of construction to be capitalized. All other expenses including interest incurred during construction period are capitalized as a part of the construction cost to the extent to which these expenditures are attributable to the construction as per Ind AS-23 "Borrowing Costs". Interest income earned on temporary investment of funds brought in for the project during construction period are set off from the interest expense accounted for as expenditure during the construction period.

**3.2 Impairment of non-financial assets**

The carrying amounts of assets are reviewed at each balance sheet date if there is any indication of impairment based on internal/external factors. An impairment loss is recognized wherever the carrying amount of an asset exceeds its recoverable amount. The recoverable amount is the greater of the asset's net selling price and value in use. In assessing value in use, the Company measures it on the basis of discounted cash flows for the remaining year's (remaining useful life) projections estimated based on current prices. Assessment is also done at each Balance Sheet date as to whether there is any indication that an impairment loss recognized for an asset in prior accounting periods may no longer exist or may have decreased. After impairment, depreciation is provided on the revised carrying amount of the asset over its remaining useful life.

**3.3 Foreign Currency Transactions**

The Company's financial statements are presented in INR, which is also the Company's functional currency.

Initial Recognition

Foreign currency transactions are recorded in the reporting currency, by applying to the foreign currency amount the exchange rate between the reporting currency and the foreign currency at the date of transaction.

Conversion

Foreign currency monetary items are reported using the closing rate. Non-monetary items, which are measured in terms of historical costs denominated in foreign currency, are reported using the exchange rate at the date of the transaction. Non-monetary items, which are measured at fair value or other similar valuation denominated in a foreign currency, are translated using the exchange rate at the date when such value was determined.

Exchange Differences

Exchange differences arising on the settlement of monetary items or on reporting Company's monetary items at rates different from those at which they were initially recorded during the year, or reported in previous financial statements including receivables and payables which are likely to

**DINESH REMEDIES LIMITED**  
**NOTES ANNEXED TO AND FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31ST MARCH, 2020**

be settled in foreseeable future, are recognized as income or as expenses in the year in which they arise. All other exchange differences are recognized as income or as expenses in the period in which they arise.

Transactions covered under forward contracts are accounted for at the contracted rate. All export proceeds have been accounted for at a fixed rate of exchange at the time of raising invoices. Foreign exchange fluctuations as a result of the export sales have been adjusted in the statement of profit and loss account and export proceeds not realized at the balance sheet date are restated at the rate prevailing as at the balance sheet date.

### **3.4 Revenue recognition**

Revenue is recognized to the extent it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Specifically,

- (i) Domestic Sales and Export Sales are recognized and accounted on dispatch of products to the customers. Sales are disclosed at net of discount and returns as, applicable and exclusive of GST.
- (ii) Export benefits in respect of exports made under the various export schemes of the Government are recognized based on the reasonable certainty of their receipt from the statutory authorities.
- (iii) Claims receivable on account of Insurance are accounted for to the extent the Company is reasonably certain of their ultimate collection.

### **3.5 Financial Instruments**

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

#### **A. Financial Assets**

##### **a. Initial recognition and measurement:**

All financial assets are recognized initially at fair value (FVOCI / amortized cost / FVTPL). Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place [regular way trades] are recognized on the settlement date, trade date, i.e., the date that the Company commits to purchase or sell the asset.

##### **b. Subsequent measurement:**

For purposes of subsequent measurement, financial assets are classified in four categories:

##### **i. Debt instruments at amortized cost:**

A 'debt instrument' is measured at the amortized cost if both the following conditions are met:

- The asset is held with an objective of collecting contractual cash flows
- Contractual terms of the asset give rise on specified dates to cash flows that are "solely payments of principal and interest" [SPPI] on the principal amount outstanding.

After initial measurement, such financial assets are subsequently measured at amortized cost using the effective interest rate [EIR] method. Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortization is included in finance income in the Statement of Profit and Loss. The losses arising from impairment are recognized in the profit or loss. This category generally applies to trade and other receivables.

**DINESH REMEDIES LIMITED**  
**NOTES ANNEXED TO AND FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31ST MARCH, 2020**

**ii. Debt instruments at fair value through other comprehensive income [FVTOCI]:**

A 'debt instrument' is classified as at the FVTOCI if both of the following criteria are met:

- The asset is held with objective of both - for collecting contractual cash flows and selling the financial assets
- The asset's contractual cash flows represent SPPI.

Debt instruments included within the FVTOCI category are measured initially as well as at each reporting date at fair value. Fair value movements are recognized in the other comprehensive income [OCI]. However, the Company recognizes interest income, impairment losses & reversals and foreign exchange gain or loss in the Statement of Profit and Loss. On derecognition of the asset, cumulative gain or loss previously recognized in OCI is reclassified from the equity to Statement of Profit and Loss.

**iii. Debt instruments, derivatives and equity instruments at fair value through profit or loss [FVTPL]:**

FVTPL is a residual category for debt instruments. Any debt instrument, which does not meet the criteria for categorization as at amortized cost or as FVTOCI, is classified as at FVTPL. Debt instruments included within the FVTPL category are measured at fair value with all changes recognized in the P&L.

**iv. Equity instruments measured at fair value through other comprehensive income [FVTOCI]:**

All equity investments in scope of Ind AS 109 are measured at fair value. Equity instruments which are held for trading and contingent consideration recognized by an acquirer in a business combination to which Ind AS103 applies are classified as at FVTPL. For all other equity instruments, the Company may make an irrevocable election to present in other comprehensive income subsequent changes in the fair value. The Company has made such election on an instrument by- by instrument basis. The classification is made on initial recognition and is irrevocable. If the Company decides to classify an equity instrument as at FVTOCI, then all fair value changes on the instrument, excluding dividends, are recognized in the OCI. There is no recycling of the amounts from OCI to Statement of Profit and Loss, even on sale of investment. However, the Company may transfer the cumulative gain or loss within equity. Equity instruments included within the FVTPL category are measured at fair value with all changes recognized in the Statement of Profit and Loss.

**c. Derecognition:**

A financial asset is primarily derecognized when:

- i. The Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a 'pass-through' arrangement and either [a] the Company has transferred substantially all the risks and rewards of the asset, or [b] the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

**B. Financial liabilities:**

**a. Initial recognition and measurement:**

Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings, payables, or as over the counter derivatives designated as hedging instruments in an effective hedge, as appropriate. All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

**DINESH REMEDIES LIMITED**  
**NOTES ANNEXED TO AND FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31ST MARCH, 2020**

**b. Subsequent measurement:**

The measurement of financial liabilities depends on their classification, as described below:

**i. Financial liabilities at fair value through profit or loss:**

Financial liabilities at fair value through profit or loss include financial liabilities held for trading and financial liabilities designated upon initial recognition as at fair value through profit or loss. This category also includes over the counter derivative financial instruments entered into by the Company that are not designated as hedging instruments in hedge relationships as defined by Ind AS 109.

Financial liabilities designated upon initial recognition at fair value through profit or loss are designated as such at the initial date of recognition, and only if the criteria in Ind AS 109 are satisfied for liabilities designated as FVTPL, fair value gains/ losses attributable to changes in own credit risk are recognized in OCI. These gains/ losses are not subsequently transferred to P&L. However, the Company may transfer the cumulative gain or loss within equity. All other changes in fair value of such liability are recognized in the statement of profit or loss. The Company has not designated any financial liability as at fair value through profit and loss.

**ii. Loans and borrowings:**

After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortized cost using the EIR method. Gains and losses are recognized in profit or loss when the liabilities are derecognized as well as through the EIR amortization process. Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortization is included as finance costs in the statement of profit and loss.

**c. Derecognition:**

A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognized in the statement of profit or loss.

**C. Reclassification of financial assets:**

The Company determines classification of financial assets and liabilities on initial recognition. After initial recognition, no reclassification is made for financial assets which are equity instruments and financial liabilities. For financial assets which are debt instruments, a reclassification is made only if there is a change in the business model for managing those assets. Changes to the business model are expected to be infrequent. If the Company reclassifies financial assets, it applies the reclassification prospectively from the reclassification date which is the first day of the immediately next reporting period following the change in business model. The Company does not restate any previously recognized gains, losses [including impairment gains or losses] or interest.

**D. Offsetting of financial instruments:**

Financial assets and financial liabilities are offset and the net amount is reported in the balance sheet if there is a currently enforceable legal right to offset the recognized amounts and there is an intention to settle on a net basis, to realize the assets and settle the liabilities simultaneously.

**DINESH REMEDIES LIMITED**  
**NOTES ANNEXED TO AND FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31ST MARCH, 2020**

**3.6 Fair Value Measurement**

The Company measures financial instruments at fair value at each balance sheet date. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- a. In the principal market for the asset or liability, or
- b. In the absence of a principal market, in the most advantageous market for the asset or liability

The principal or the most advantageous market must be accessible by the Company. The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- Level 1 — Quoted [unadjusted] market prices in active markets for identical assets or liabilities
- Level 2 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable
- Level 3 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable

**3.7 Inventories**

- i. Stores, Machinery Spares, etc. are valued at cost or net realizable value whichever is lower. Cost is arrived at on 'Moving Weighted Average Cost basis.
- ii. Raw Materials are valued at cost or net realizable value whichever is lower. Cost is arrived at on 'Annual Weighted Average Cost basis'.
- iii. Material in progress is valued at cost or net realizable value whichever is lower.
- iv. Finished goods are valued at cost or net realizable value whichever is lower.

**3.8 Retirement benefits**

i. Defined Contribution Plan

Company's contribution paid/payable during the period to Provident Fund, EDLI, Officer Super annuation Fund and Labour Welfare Fund are recognized in the Profit & Loss Account.

ii. Defined Benefit Plan

Provision for payments to the Employees Gratuity is based on actuarial valuation done at the close of each financial year. At the reporting date, Company's liabilities towards gratuity is determined by independent actuarial valuation using the projected unit credit method which considers each period of service as giving rise to an additional unit of benefit entitlement and measures each unit separately to build up final obligation. Past services are recognized on a straight-line basis over the average period until the amended benefits become vested. Actuarial gain and losses are recognized immediately in the statement of Profit and Loss account as income or expenses. Obligation is measured at the present value of estimated future cash flows using a discounted rate that is determined by reference to market yields at the Balance Sheet date on Government Bonds, where the currency and terms of the Government Bonds are consistent with the currency and estimated

**DINESH REMEDIES LIMITED**  
**NOTES ANNEXED TO AND FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31ST MARCH, 2020**

terms of the defined benefit obligation. Company recognizes the undiscounted amount of Short term employee benefits during the accounting period based on service rendered by the employees.

Re-measurements, comprising of actuarial gains and losses, the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability and the return on plan assets (excluding amounts included in net interest on the net defined benefit liability), are recognized immediately in the balance sheet with a corresponding debit or credit to other comprehensive income in the period in which they occur. Re-measurements are not classified to the statement of profit and loss in subsequent periods.

Net interest is calculated by applying the discount rate to the net defined benefit liability or asset.

### **3.9 Taxes on Income**

Tax expense comprises current and deferred tax. Current income tax is measured at the amount expected to be paid to the tax authorities in accordance with the Income Tax Act, 1961 and tax laws prevailing in the respective tax jurisdictions where the Company operates. Current tax items are recognized in correlation to the underlying transaction either in P&L, OCI or directly in equity.

Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.

Deferred tax liabilities are recognized for all taxable temporary differences. Deferred tax assets are recognized for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses. As at 31<sup>st</sup> March, 2020, the company is having net deferred tax assets and the same are recognized only if there reasonable certainty that the company will be having sufficient future taxable profits and based on the same the DTA may be recognized in the books.

The carrying amount (if any) of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Unrecognized deferred tax assets are re-assessed at each reporting date and are recognized to the extent the management estimates that it has become reasonable that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates [and tax laws] that have been enacted or substantively enacted at the reporting date.

Deferred tax items are recognized in correlation to the underlying transaction either in OCI or directly in equity. Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current tax liabilities.

### **3.10 Borrowing costs**

Borrowing cost includes interest, amortization of ancillary costs incurred in connection with the arrangement of borrowings and exchange differences arising from foreign currency borrowings to the extent they are regarded as an adjustment to the interest cost.

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalized as part of the cost of the respective asset. All other borrowing costs are expensed in the period they occur.

Borrowing costs which are not specifically attributable to the acquisition, construction or production of a qualifying asset, the amount of borrowing costs eligible for capitalization is determined by applying

**DINESH REMEDIES LIMITED**  
**NOTES ANNEXED TO AND FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31ST MARCH, 2020**

a weighted average capitalization rate. The weighted average rate is taken of the borrowing costs applicable to the outstanding borrowings of the company during the period, other than borrowings made specifically for the purpose of obtaining a qualifying asset. The amount of borrowing costs capitalized cannot exceed the amount of borrowing costs incurred during that period.

**3.11 Earnings per equity share**

Basic earnings per share is calculated by dividing the net profit or loss from continuing operation and total profit, both attributable to equity shareholders of the Company by the weighted average number of equity shares outstanding during the period.

**3.12 Provisions, Contingent Liabilities and Contingent Assets:**

Provision is recognized when the Company has a present obligation (legal or constructive) as a result of past events and it is probable that the outflow of resources will be required to settle the obligation and in respect of which reliable estimates can be made.

A disclosure for contingent liability is made when there is a possible obligation, that may, but probably will not require an outflow of resources. When there is a possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision/disclosure is made. The Company does not recognize a contingent liability but discloses its existence in the financial statements.

Contingent assets are not recognized in the financial statements. Provisions and contingencies are reviewed at each balance sheet date and adjusted to reflect the correct management estimates.

If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, using a current pre-tax rate that reflects, when appropriate, the risks specific to the liability. Commitments include the amount of purchase order (net of advances) issued to parties for completion of assets. Provisions, contingent liabilities, contingent assets and commitments are renewed at each balance sheet date.

**3.13 Cash and Cash Equivalents**

Cash and cash equivalent comprise cash on hand and demand deposits with banks which are short-term, highly liquid investments that are readily convertible into known amounts of cash and which are subject to insignificant risk of changes in value.

**3.14 Exceptional items**

Certain occasions, the size, type or incidence of an item of income or expense, pertaining to the ordinary activities of the Company is such that its disclosure improves the understanding of the performance of the Company, such income or expense is classified as an exceptional item and accordingly, disclosed in the notes accompanying to the financial statements.



**DINESH REMEDIES LIMITED**  
**Regd. Office: Shri Dinesh Mills premises, Akota Road,**  
**Vadodara – 390 020**  
**(CIN: U24230GJ2005PLC045447)**

=====

**FIFTEENTH ANNUAL GENERAL MEETING**

**ATTENDANCE SLIP**

Folio No.: \_\_\_\_\_

No. of Shares: \_\_\_\_\_

Name of Proxy (if any) \_\_\_\_\_

I/We hereby record my/our presence at the 15<sup>th</sup> Annual General Meeting of the Company being held at Registered Office of the Company at Shri Dinesh Mills premises, Akota Road, Vadodara on Wednesday, the 5<sup>th</sup> August, 2020 at 5.00 p.m.

-----  
Member's / Proxy's Signature

Notes:

1. Please complete the Folio Number and Name, sign this Attendance Slip and hand it over at the Attendance verification counter at the entrance of the Meeting Hall.
2. Members holding shares in physical form are requested to advise the change in their address, if any to the Registrar / Company quoting their Folio Number(s).
3. Member intending to appoint a proxy, should complete the proxy form printed below and deposit it at the Company's Registered Office not later than 48 hours before the commencement of the Annual General Meeting.

**DINESH REMEDIES LIMITED**  
**Regd. Office: Shri Dinesh Mills premises, Akota Road,**  
**Vadodara – 390 020**  
**(CIN: U24230GJ2005PLC045447)**

=====

PROXY FORM

-----

Name of Member(s):  
Registered Address:  
Email ID:  
Folio No.

-----

I/We, being a Member /Members of Dinesh Remedies Limited hereby appoint:

1. Name :  
Address:  
E-mail ID:  
Signature \_\_\_\_\_ or failing him
  
2. Name :  
Address:  
E-mail ID:  
Signature \_\_\_\_\_ or failing him
  
3. Name :  
Address:  
E-mail ID:  
Signature \_\_\_\_\_ or failing him

as my/our Proxy to attend and (on a poll) for me/us and on my/our behalf at the 15<sup>th</sup> Annual General Meeting of the Company, to be held on Wednesday, the 5<sup>th</sup> August, 2020 at 5.00 p.m. at the Registered Office of the Company and at any adjournment thereof in respect of such Resolutions as are indicated below:

Resolution No.	Resolutions	Optional *	
		For	Against
1	Adoption of Audited Financial Statement.		
2	Appointment of Shri Dixit Patel (DIN-01169162), who retires by rotation and being eligible, offers himself for re-appointment.		

Signed this on \_\_\_\_\_ day of \_\_\_\_\_ 2020

Signature of Shareholder: \_\_\_\_\_

Signature of Proxy Holder(s): \_\_\_\_\_

Affix  
Revenue  
Stamp Re.1

**Note:**

1. The Proxy should be deposited at the Registered Office of the Company not later than 48 hours before the commencement of the Annual General Meeting.
2. For this Resolution and explanatory statement and notes, please refer to the Notice of the 15<sup>th</sup> Annual General Meeting.
- \*3. It is optional to put a 'X' in the appropriate column against the Resolution indicated in the Box. If you leave the 'for' or 'against' column blank against any or all Resolutions, your proxy will be entitle to vote in the manner as he/she thinks appropriate.
4. Please complete all details including details of manner(s) in above box before submission.